



Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases

Giovanni Palermo, Sonia Mazzucchi, Alessandra Della Vecchia, Gabriele Siciliano, Ubaldo Bonuccelli, Carole Azuar, Roberto Ceravolo, Simone Lista, Harald Hampel, Filippo Baldacci

► To cite this version:

Giovanni Palermo, Sonia Mazzucchi, Alessandra Della Vecchia, Gabriele Siciliano, Ubaldo Bonuccelli, et al.. Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases. *Molecular Neurobiology*, 2020, 57 (11), pp.4667-4691. 10.1007/s12035-020-02035-9 . hal-03385896

HAL Id: hal-03385896

<https://hal.sorbonne-universite.fr/hal-03385896>

Submitted on 19 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Dear Author

Here are the proofs of your article.

- You can submit your corrections **online** or by **fax**.
- For **online** submission please insert your corrections in the online correction form. Always indicate the line number to which the correction refers.
- Please return your proof together with the permission to publish confirmation.
- For **fax** submission, please ensure that your corrections are clearly legible. Use a fine black pen and write the correction in the margin, not too close to the edge of the page.
- Remember to note the journal title, article number, and your name when sending your response via e-mail, fax or regular mail.
- **Check** the metadata sheet to make sure that the header information, especially author names and the corresponding affiliations are correctly shown.
- **Check** the questions that may have arisen during copy editing and insert your answers/corrections.
- **Check** that the text is complete and that all figures, tables and their legends are included. Also check the accuracy of special characters, equations, and electronic supplementary material if applicable. If necessary refer to the *Edited manuscript*.
- The publication of inaccurate data such as dosages and units can have serious consequences. Please take particular care that all such details are correct.
- Please **do not** make changes that involve only matters of style. We have generally introduced forms that follow the journal's style. Substantial changes in content, e.g., new results, corrected values, title and authorship are not allowed without the approval of the responsible editor. In such a case, please contact the Editorial Office and return his/her consent together with the proof.
- If we do not receive your corrections **within 48 hours**, we will send you a reminder.

Please note

Your article will be published **Online First** approximately one week after receipt of your corrected proofs. This is the **official first publication** citable with the DOI.

Further changes are, therefore, not possible.

After online publication, subscribers (personal/institutional) to this journal will have access to the complete article via the DOI using the URL:

<http://dx.doi.org/10.1007/s12035-020-02035-9>

If you would like to know when your article has been published online, take advantage of our free alert service. For registration and further information, go to:

<http://www.springerlink.com>.

Due to the electronic nature of the procedure, the manuscript and the original figures will only be returned to you on special request. When you return your corrections, please inform us, if you would like to have these documents returned.

The **printed version** will follow in a forthcoming issue.

32	Author	Family Name	Vecchia
33		Particle	
34		Given Name	Alessandra Della
35		Suffix	
36		Organization	University of Pisa
37		Division	Department of Clinical and Experimental Medicine
38		Address	Pisa, Italy
39		e-mail	
40		Family Name	Siciliano
41		Particle	
42		Given Name	Gabriele
43		Suffix	
44		Organization	University of Pisa
45	Author	Division	Department of Clinical and Experimental Medicine
46		Address	Pisa, Italy
47		e-mail	
48		Family Name	Bonuccelli
49		Particle	
50		Given Name	Ubaldo
51		Suffix	
52		Organization	University of Pisa
53	Author	Division	Department of Clinical and Experimental Medicine
54		Address	Pisa, Italy
55		e-mail	
56		Family Name	Azuar
57		Particle	
58		Given Name	Carole
59		Suffix	
60		Organization	AP-HP - Hôpital Pitié-Salpêtrière
61	Author	Division	Centre National de Référence des Démences Rares ou Précoces, IM2A, Département de Neurologie
62		Address	Paris, France
63		Organization	Institut du Cerveau et de la Moelle épinière (ICM)
64		Division	FrontLab
65		Address	Paris, France
66		e-mail	
67	Author	Family Name	Ceravolo
68		Particle	

69		Given Name	Roberto
70		Suffix	
71		Organization	University of Pisa
72		Division	Department of Clinical and Experimental Medicine
73		Address	Pisa, Italy
74		e-mail	
75		Family Name	Lista
76		Particle	
77		Given Name	Simone
78		Suffix	
79		Organization	Sorbonne University
80		Division	GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital
81	Author	Address	Boulevard de l'hôpital, Paris, France
82		Organization	Brain & Spine Institute (ICM)
83		Division	INSERM U 1127, CNRS UMR 7225
84		Address	Boulevard de l'hôpital, Paris, France
85		Organization	Pitié-Salpêtrière Hospital
86		Division	Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A)
87		Address	Paris, France
88		e-mail	
89		Family Name	Hampel
90		Particle	
91		Given Name	Harald
92		Suffix	
93	Author	Organization	Institut du Cerveau et de la Moelle épinière (ICM)
94		Division	FrontLab
95		Address	Paris, France
96		e-mail	
97		Received	10 May 2020
98	Schedule	Revised	
99		Accepted	22 July 2020
100	Abstract	One of the most pressing challenges in the clinical research of neurodegenerative diseases (NDDs) is the validation and standardization of pathophysiological biomarkers for different contexts of use (CoUs), such as early detection, diagnosis, prognosis, and prediction of treatment response. Neurofilament light chain (NFL) concentration is a particularly promising candidate, an indicator of axonal degeneration, which can be analyzed in peripheral blood with advanced ultrasensitive methods. Serum/plasma NFL	

concentration is closely correlated with cerebrospinal fluid NFL and directly reflects neurodegeneration within the central nervous system. Here, we provide an update on the feasible CoU of blood NFL in NDDs and translate recent findings to potentially valuable clinical practice applications. As NFL is not a disease-specific biomarker, however, blood NFL is an easily accessible biomarker with promising different clinical applications for several NDDs: (1) early detection and diagnosis (i.e., amyotrophic lateral sclerosis, Creutzfeldt–Jakob disease, atypical parkinsonisms, sporadic late-onset ataxias), (2) prognosis (Huntington’s disease and Parkinson’s disease), and (3) prediction of time to symptom onset (presymptomatic mutation carriers in genetic Alzheimer’s disease and spinocerebellar ataxia type 3).

101	Keywords separated by ' - '	Alzheimer’s disease - Amyotrophic lateral sclerosis - Biomarkers - Creutzfeldt–Jakob disease - NFL - Parkinsonian syndromes
102	Foot note information	Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases

Giovanni Palermo¹ · Sonia Mazzucchi¹ · Alessandra Della Vecchia¹ · Gabriele Siciliano¹ · Ubaldo Bonuccelli¹ · Carole Azuar^{2,3} · Roberto Ceravolo¹ · Simone Lista^{4,5,6} · Harald Hampel³ · Filippo Baldacci^{1,3}

Received: 10 May 2020 / Accepted: 22 July 2020
© Springer Science+Business Media, LLC, part of Springer Nature 2020

Abstract

One of the most pressing challenges in the clinical research of neurodegenerative diseases (NDDs) is the validation and standardization of pathophysiological biomarkers for different contexts of use (CoUs), such as early detection, diagnosis, prognosis, and prediction of treatment response. Neurofilament light chain (NFL) concentration is a particularly promising candidate, an indicator of axonal degeneration, which can be analyzed in peripheral blood with advanced ultrasensitive methods. Serum/plasma NFL concentration is closely correlated with cerebrospinal fluid NFL and directly reflects neurodegeneration within the central nervous system. Here, we provide an update on the feasible CoU of blood NFL in NDDs and translate recent findings to potentially valuable clinical practice applications. As NFL is not a disease-specific biomarker, however, blood NFL is an easily accessible biomarker with promising different clinical applications for several NDDs: (1) early detection and diagnosis (i.e., amyotrophic lateral sclerosis, Creutzfeldt–Jakob disease, atypical parkinsonisms, sporadic late-onset ataxias), (2) prognosis (Huntington’s disease and Parkinson’s disease), and (3) prediction of time to symptom onset (presymptomatic mutation carriers in genetic Alzheimer’s disease and spinocerebellar ataxia type 3).

Keywords Alzheimer’s disease · Amyotrophic lateral sclerosis · Biomarkers · Creutzfeldt–Jakob disease · NFL · Parkinsonian syndromes

Introduction

Neurodegenerative diseases (NDDs) are currently considered as a continuum of disorders with common pathophysiological

mechanisms, including misfolded protein deposition, neuronal synaptic disruption, axonal degeneration, neuroinflammation, and oxidative stress [1–3]. Therefore, the greatest current challenge in the field of NDDs is to provide biomarkers for the pathological mechanisms underlying each clinical picture [4], in order to improve the diagnostic and prognostic stratification of the patients and to allow early diagnosis and disease monitoring as well as to test treatment efficacy.

Within this multifaceted *scenario*, neurofilament light chain (NFL) is, at the present, the most promising candidate biomarker for an early identification of a general neurodegenerative process able to support disease diagnosis, prognosis, and progression, as well as monitoring an eventual disease-modifying treatment [5–7]. It is a component of neurofilaments (NFs) that, together with glial filaments, are the main types of intermediate filaments (IFs) of the nervous system [9–11]. Its physiological function is to confer mechanical stress resistance by preserving the characteristic cellular shape, intracellular traffic regulation between axons and dendrites, and, indirectly, nerve conduction speed modulation maintaining axon diameter [11]. Recent research suggests that they are also important for normal synaptic function [12]. Axonal dysfunction and degeneration are

✉ Filippo Baldacci
filippo.baldacci@unipi.it

¹ Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
² Centre National de Référence des Démences Rares ou Précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France
³ FrontLab, Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
⁴ GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Sorbonne University, Boulevard de l’hôpital, Paris, France
⁵ INSERM U 1127, CNRS UMR 7225, Brain & Spine Institute (ICM), Boulevard de l’hôpital, Paris, France
⁶ Department of Neurology, Institute of Memory and Alzheimer’s Disease (IM2A), Pitié-Salpêtrière Hospital, Paris, France

important steps in NDD pathogenesis, occurring long before neuronal cell death and often preceding detectable deposition of misfolded proteins [8]. During these processes, NFL is released into the extracellular space and, consequently, into body fluids, such as the cerebrospinal fluid (CSF) and blood.

Broadly speaking, mounting data reported increased CSF NFL levels in NDDs [5, 6, 13]. In the mid-1990s, through the first enzyme-linked immunosorbent assay (ELISA) developed for NFL, Rosengren and colleagues [14] demonstrated that CSF NFL concentration was increased in amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), and vascular cognitive impairment (VCI). Although with different magnitudes, further studies revealed that CSF NFL increased also in other several NDDs, such as frontotemporal dementia (FTD) [15, 16], Parkinson's disease (PD) and atypical parkinsonisms (APs) [17, 18], Huntington's disease (HD) [19], mild cognitive impairment (MCI) [20, 21], and Creutzfeldt–Jakob disease (CJD) [22, 23], as well as in non-primary neurodegenerative disorders, such as multiple sclerosis (MS) [24], neuroinfectious conditions [25], traumatic brain injury [26], acute stroke [27], and cerebrovascular diseases [28]. Moreover, in NDDs, CSF NFL levels showed to correlate with poorer cognition, short survival times, brain atrophy, and disease severity and progression [29–31], supporting the notion that it could be useful not only as a diagnostic biomarker but also as a prognostic and progression biomarker [32]. As a result, it has been proposed as a dynamic biomarker for axonal degeneration [5, 6, 13] with the potential capacity to monitor treatment effectiveness [10, 33].

In the last few years, the interest in NFL research shifted toward blood. An ideal biomarker should be easily measurable, accurate, quantitative, reproducible, and employable to exactly categorize the population in line with a certain disease [34, 35]. To this end, blood-based biomarkers would have significant advantages in time efficiency and cost efficiency compared to CSF and neuroimaging [36, 37]. Moreover, they would offer potential applications at the population level as screening tools in primary care, as well as for longitudinal evaluations with repeated sampling during follow-up. It is not surprising that brain pathophysiological processes are reflected into the periphery. However, CSF proteins partially enters the blood flow, are subsequently diluted in a greater volume compared with CSF, and go through biochemical interactions with a large amount of plasma proteins. They are also cleared by blood cells and metabolized by other tissues. Finally, these processes overall hamper their measurement in plasma or serum using traditional techniques. Nevertheless, in the past few years, the development of analytical tools for ultrasensitive quantification—the immunomagnetic reduction (IMR) and the single molecule array (Simoa) techniques—by allowing an efficient measurement of NFL in blood [38], charted a tight correlation between CSF and blood NFL in different NDDs [39]. Therefore, blood NFL was suggested

as a proxy of any neurodegenerative process, paving the way to its use in clinical practice as a reliable risk biomarker for neurodegeneration [40, 41]. Nonetheless, its potential application in real life remains unclear [42].

Biomarker is defined as “a characteristic that is objectively measured and evaluated as an indicator of normal biologic and pathogenic processes, or pharmacologic responses to a therapeutic intervention” [43]. From a clinical perspective, a biomarker can be also classified in further categories with some practical and conceptual overlaps: (1) antecedent biomarkers identifying a risk of disease development (*risk biomarkers*), (2) early biomarkers screening a subclinical condition (*screening biomarkers*), (3) biomarkers specifically recognizing a full-blown clinical picture (*diagnostic biomarkers*), (4) biomarkers categorizing disease severity (*staging biomarkers*), (5) biomarkers predicting future disease course (*prognostic biomarkers*), and (6) biomarkers predicting treatment response (*predicting or monitoring biomarkers*) [44]. Accordingly, it is crucial to define the context of use of a certain biomarker (primary care screening, diagnostic, risk of progression, disease monitoring, stratification for clinical trials, and pharmacodynamic or treatment response monitoring).

This review will attempt to summarize the current literature on blood (plasma or serum) NFL in NDDs, trying to translate research data in practical considerations, focusing on the context of use of blood NFL as a biomarker in the framework of the NDDs (Table 1).

Literature Research Methods

We conducted a systematic review of the literature until February 2020, using the key terms “NFL,” “neurofilament light chain,” and “neurofilament” to interrogate the PubMed database for articles published in English evaluating blood NFL concentrations (serum and plasma) in NDDs. Overall, we identified 38 studies. The use of internationally accepted clinical diagnostic criteria for each NDD, in particular AD [45–49], ALS [50–52], dementia with Lewy bodies (DLB) [53–55], FTD [56–58], PD [59–61], AP [62–65], and sporadic Creutzfeldt–Jakob disease (sCJD) [66, 67], has been checked out for any single study. The diagnostic performance of blood NFL concentrations to correctly allocate the participants to the different diagnostic groups was considered as follows: “excellent” (area under the ROC curve (AUROC) 0.90–1.00), “good” (AUROC 0.80–0.89), “fair” (AUROC 0.70–0.79), “poor” (AUROC 0.60–0.69), or “fail” (i.e., no discriminatory capacity) (AUROC 0.50–0.59) [68].

AD

AD is the most common form of dementia in the elderly, accounting for 50–70% of prevalent neurodegenerative

Table 1 Overview on the possible context of use of blood NFL as a biomarker in NDDs

		Diagnostic value			Prognostic value	Monitoring treatment
		Preclinical phase	Prodromal phase	Full-blown picture		
	AD	±	+	+	+	±
	PD	±	±	+	+	±
	Atypical parkinsonisms (4R tauopathies)	±	±	+	+	±
	DLB	±	±	±	±	±
	FTD	—	±	+	±	±
	ALS	±	±	+	±	±
	CJD	±	+	+	—	±
	HD	—	—	—	+	±
	SMA	—	—	—	±	+
	Sporadic late-onset ataxias	±	±	±	+	±
	NDDs as a whole	±	+	+	+	±

Plus sign (+), potential use, supportive data are available; plus-minus sign (±), unknown; negative sign, negative evidences are available

AD Alzheimer’s disease, ALS amyotrophic lateral sclerosis, CJD Creutzfeldt–Jakob disease, DLB dementia with Lewy body, FTD frontotemporal dementia, HD Huntington’s disease, NDD neurodegenerative diseases, PD Parkinson’s disease, SMA spinal muscular atrophy

dementia cases with an enormous health and economic impact [69]. The scientific and clinical research is nowadays shifting from dementia to the prodromal or even preclinical phases of AD to find effective therapeutic interventions that can delay or halt neurodegenerative progression [70, 71].

Biomarkers hold promise for improving early diagnosis in AD and establishing a tailored approach. The use of specific surrogate biomarkers (neuroimaging, blood [plasma/serum], and CSF) of AD pathology has been included in revised diagnostic criteria to distinguish AD from other forms of dementia since its early disease stages. However, postmortem studies demonstrate a high degree of neuropathologic heterogeneity in patients who received a clinical diagnosis of AD [72]. The pathogenesis of AD involves interacting pathophysiological cascades in which the deposition of amyloid plaques (A β) and the formation of neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein would represent only the core events. The recently established “A/T/N” scheme proposes three binary biomarker categories which reflect AD pathophysiology, where “A” refers to A β pathology, “T” to tau pathology, and N to neurodegeneration [73, 74]. However, emerging evidence stresses the existence of additional molecular pathophysiological pathways, such as synaptic dysfunction and degeneration, innate immune response and neuroinflammation, vascular and cell membrane dysregulation, brain metabolic dysfunction, and axonal disruption [75]. The latter is prominent in AD, and it is more closely related to cognitive decline than A β pathology [76], thus leading to propose CSF NFL as a non-specific biomarker to detect early AD pathophysiological alterations [77]. In addition, an increased release of NFL molecules is a consequence of aging that contributes to an axonal degeneration due to subclinical cerebrovascular changes and neuronal atrophy [78]. In this regard, a recent

prospective community-based study enrolling a cohort of cognitively intact subjects reported high variability of serum NFL levels above 60 years [79].

Several studies showed that CSF NFL levels are elevated in AD patients when compared with healthy controls (HCs) and higher NFL concentration is predictive of a rapid disease progression along core biomarkers of AD pathology [21]. Peripheral serum or plasma NFL strongly correlated with CSF NFL concentration, suggesting that it reflects the same pathological process [80]. In general, we found that the levels of NFL are higher in serum than in plasma, but the majority of studies used plasma to quantify NFL.

NFL as Diagnostic Biomarker

Current evidence revealed that plasma NFL allows to discriminate AD patients from HC subjects with a good/excellent diagnostic accuracy [77, 81] (Table 2). In addition, plasma NFL levels showed to be higher in the AD dementia group than in the MCI group and in A β -positive MCI patients than HC [77]. More recently, this finding has been replicated in a larger study in the Dominantly Inherited Alzheimer Network (DIAN) [82]. Other studies reported higher plasma/serum NFL levels in AD and MCI patients compared with controls [76, 83, 84], but with conflicting results about the differences between MCI and cognitively normal individuals. A recent meta-analysis by Wang and colleagues [85] confirmed these findings, supporting a possible contribute of plasma NFL in the AD diagnostic workup. Moreover, plasma NFL levels could also reflect NFT pathology (as determined by NFL immunostaining) and neurodegeneration at post-mortem evaluation [76].

Table 2 The utility of NFL in the diagnostic and progression evaluation of neurodegenerative diseases

	First author (type of study)	Controls	Patients	Diagnostic/prognostic value of blood NFL	Notes
t2.1	AD				
t2.2	Preische, 2019 (longitudinal study)	HC (AD mutation non-carriers) $n = 162$	AD presymptomatic mutation carriers, $n = 243$	- Rate of change of serum NFL in differentiating non-mutation carriers vs presymptomatic mutation carriers, AUROC = 0.7 - Non-mutation carriers vs symptomatic non-mutation carriers, AUROC = 0.89 - Baseline serum NFL value in differentiating non-mutation carriers vs presymptomatic mutation carriers, AUROC = 0.49 (at the cutoff value of 37.4 pg/mL) - Non-mutation carriers vs symptomatic non-mutation carriers, AUROC = 0.85 (at the cutoff value of 27.9 pg/mL) - Plasma NFL in differentiating patients vs HC, AUROC = 0.85 (95% CI 0.772–0.934), unadjusted for other variables - AD vs HC, AUROC = 0.92 (95% CI 0.869–0.970), adjusted for age - At the cutoff maximizing Youden index, 25.7 pg/mL, the unconditional accuracy was 0.82	- Mutation carriers were subdivided into 3 groups: presymptomatic mutation carriers (individuals who scored 0 on the CDR scale across all visits), converters (CDR = 0 at baseline and CDR > 0 at subsequent visits), and symptomatic mutation carriers (CDR > 0 across all visits)
t2.3	Lewczuk, 2018 (cross-sectional study)	HC = 41	MCI-AD = 25 ADD = 33 AD = 58	- Plasma NFL in differentiating patients vs HC, AUROC = 0.85 (95% CI 0.772–0.934), unadjusted for other variables - AD vs HC, AUROC = 0.92 (95% CI 0.869–0.970), adjusted for age - At the cutoff maximizing Youden index, 25.7 pg/mL, the unconditional accuracy was 0.82	- MCI-AD were AD patients at the stage of MCI - ADD were AD patients at the stage of early dementia - AD included MCI-AD + AD patients
t2.4	Mattsson, 2017 (longitudinal study)	HC = 193	AD = 180 MCI = 197 pMCI = 109 sMCI = 65	- Plasma NFL in differentiating AD vs CNC, AUROC = 0.87 (correcting for age, sex, educational level, and <i>APOE</i> $\epsilon 4$ genotype). When only correcting for age, sex, and educational level, the AUROC was reduced to 0.79	- Patients were recruited from the ADNI cohort - MCI patients were divided into stable MCI (sMCI, with no progression to dementia during ≥ 2-year follow-up) and progressive MCI (pMCI, with conversion to dementia)
t2.5	FTD				
t2.6	van der Ende, 2019 (longitudinal study)	Non-carriers of a mutation in GRN, C9orf72, or MAPT = 127	Presymptomatic carriers of a mutation in GRN, C9orf72, or MAPT = 149 FTD (symptomatic carriers of a mutation in GRN, C9orf72, or MAPT) = 59	- Serum NFL in differentiating symptomatic mutation carriers vs presymptomatic mutation carriers, AUROC = 0.93 (95% CI 0.90–0.97), at the cutoff concentration of 17 pg/mL - Symptomatic mutation carriers vs non-mutation carriers, AUROC = 0.95 (95% CI 0.92–0.98), at the cutoff concentration of 17 pg/mL - Baseline serum NFL converters vs presymptomatic mutation carriers, AUROC = 0.93 (95% CI 0.89–0.98), at the cutoff level of 15.0 pg/mL	- Multicenter cohort study on families with genetic FTD in Europe and Canada - At least 2 serum samples were taken with a time interval of 6 months or more - 9 presymptomatic carriers became symptomatic during follow-up (converters) - Presymptomatic carriers or non-carrier mutations were healthy relatives of first degree at risk of FTD
t2.7	Katisko, 2019 (longitudinal study)	FTD = 91 (bvFTD = 66; nvPPA = 16; svPPA = 4; FTD-MND = 5) PPD = 34		- Serum NFL in differentiating FTD vs PPD, AUROC = 0.85 (95% CI 0.776–0.923), at the cutoff level of 19.9 pg/mL	- The PPD group included patients with a severe late-onset psychiatric disorder (psychotic, mood disorders, or both).

t2.10 **Table 2** (continued)

First author (type of study)	Controls	Patients	Diagnostic/prognostic value of blood NFL	Notes
t2.10 Al Shweiki, 2019 (cross-sectional study)	HC = 27	bvFTD = 20 Schizophrenia = 11 Depression = 28 Bipolar disorder = 11	- bvFTD vs PPD, AUROC = 0.82 (95% CI 0.732–0.908), at the cutoff level of 19.9 pg/mL - Serum NFL in differentiating bvFTD vs HC, AUROC = 0.94 (95% CI 0.87–0.99) - bvFTD vs depression, AUROC = 0.89 (95% CI 0.8–0.98), at a cutoff level above 35.7 pg/mL - bvFTD vs bipolar disorder, AUROC = 0.94 (95% CI 0.81–1.01), at a cutoff level > 26.5 pg/mL - bvFTD vs schizophrenia, AUROC = 0.9 (95% CI 0.77–1.03), at a cutoff level > 17.7 pg/mL - Serum NFL in differentiating bvFTD vs AD, AUROC = 0.67 - bvFTD vs MCI, AUROC = 0.9 (95% CI 0.84–0.97) - bvFTD vs HC, AUROC = 0.85 (95% CI 0.72–0.97) - bvFTD vs AD subgroups selected based on CSF Aβ42 levels, AUROC = 0.79, at a cutoff value of 33 pg/mL - bvFTD vs AD subgroups selected based on both CSF Aβ42 and tau/p-tau levels, AUROC = 0.77, at a cutoff value of 34.3 pg/mL	- In the FTLD group, 26 patients had a definite diagnosis due to the C9orf72 repeat expansion - 20 bvFTD consisting of 9 possible bvFTD, 5 probable bvFTD, and 6 genetic bvFTD (4 due to C9orf72 mutations, 2 MAPT mutations) - Serum NFL levels did not differ between psychiatric and control patients - Genetic screening of 67 patients with bvFTD revealed 7 carriers for C9orf72 repeat expansion. - Analysis of MAPT and GRN in 18 patients revealed 1 carrier of the MAPT mutation and 1 carrier of the GRN mutation
t2.11 Steinacker, 2018 (longitudinal study)	HC = 15	bvFTD = 74 AD = 26 (excluding patients with normal Aβ42) AD = 11 (without the typical AD CSF biomarker pattern) MCI = 17 Subgroups were defined on the basis of both CSF Aβ42 and tau levels: - 30 bvFTD (excluding patients with decreased Aβ42) - 31 bvFTD (excluding patients with decreased Aβ42 and increased tau or p-tau) PPA = 99 (nvPPA = 40, svPPA = 38, lvPPA = 21)	- Serum NFL in differentiating bvFTD vs HC, AUROC = 0.81 (95% CI 0.72–0.91) at an optimal cutoff value > 36 pg/mL - ALS vs HC, AUROC = 0.99 (95% CI 0.98–1.00) - Serum NFL in differentiating FTD vs HC, AUROC = 0.97 (95% CI 0.93–1.00) - FTD vs presymptomatic carriers, AUROC = 0.93 (95% CI 0.87–0.98), at the cutoff level of 18.0 pg/mL	- Patients with PPA met only clinical diagnostic criteria without knowledge of fluid biomarker concentration - Participants were recruited as part of GENFI or ascertained before participation in GENFI. - 4 subjects became symptomatic during follow-up (converters)
t2.12 Steinacker, 2017 (longitudinal study)	HC = 35	PPA = 99 (nvPPA = 40, svPPA = 38, lvPPA = 21)		
t2.13 Wilke, 2016 (cross-sectional study)	HC = 46	FTD = 41 ALS = 25		
t2.14 Meeter, 2016 (longitudinal study)	HC = 71	FTD (caused by a pathogenic mutation in GRN, MAPT, or C9orf72) = 101		

Table 2 (continued)

First author (type of study)	Controls	Patients	Diagnostic/prognostic value of blood NFL	Notes
t2.15 ALS		Presymptomatic carriers of a pathogenic mutation = 62	- Presymptomatic carriers vs HC, AUROC = 0.63 (95% CI 0.51–0.75), at the cutoff level of 8.3 pg/mL - Serum NFL was also associated with survival (HR in the higher tertile 3.10, 95% CI 1.09–8.76)	
t2.16 Thouvenot, 2019 (longitudinal study)	HC = 21	ALS = 198	- Serum NFL > 15.0 pg/mL in discriminating ALS vs HC, AUROC = 0.99 (95% CI 0.972–0.999) - Patients with serum NFL levels ≥ 71.2 pg/mL had a higher risk of death (HR 4.7, 95% CI 3.0–7.4) - A cutoff NFL level of 49 pg/mL in differentiating ALS vs non-neurodegenerative controls, AUROC = 0.97 (95% CI 0.95 to 0.991) - A cutoff value of 62 pg/mL in differentiating ALS vs disease controls, AUROC = 0.87 (95% CI 0.81 to 0.935) - A cutoff value of 62 pg/mL in discriminating ALS vs all other categories considered together, AUROC = 0.88 (95% CI 0.849 to 0.926) - Patients with serum NFL above the median (125 pg/mL) had a shorter survival than patients with NFL ≤ 125 pg/mL, with an HR of 2.39 (95% CI 1.236 to 4.63)	- Patients were prospectively followed up to 18.5 months - Disease controls included in the differential diagnosis of ALS
t2.17 Verde, 2019 (longitudinal study)	Non-neurodegenerative controls = 50	ALS = 124 Disease controls = 44 FTD = 20 AD = 20 PD = 19 CJD = 6	- Serum NFL in differentiating ALS vs ALS mimic, AUROC = 0.85 (95% CI 0.79–0.90), at an optimal cutoff value of 93 pg/mL - ALS fast progressor vs ALS slow progressors, AUROC = 0.87 (95% CI 0.76–0.94), at an optimal cutoff value of 159 pg/mL - ALS vs GBS + CIDP, AUROC = 0.58 (95% CI 0.51–0.64), at an optimal cutoff value of 139 pg/mL - ALS vs HSP, AUROC = 0.84 (95% CI 0.78–0.90), at an optimal cutoff value of 55 pg/mL - ALS vs PLS, AUROC = 0.89 (95% CI 0.83–0.93), at an optimal cutoff value of 88 pg/mL - ALS vs PMA, AUROC = 0.71 (95% CI 0.63–0.78), at an optimal cutoff value of 86 pg/mL - ALS patients with serum NFL in the upper tertile had a HR = 5.34 (95% CI 1.39–20.56) vs patients with serum NFL in the low tertile.	- A subset of 16 ALS repeated serum sample showing a relative stability of NFL concentrations over time
t2.18 Gille, 2018 (longitudinal study)		ALS = 149 (C9orf72 = 15, FTD = 15, PLS = 11, PMA = 6) ALS mimic = 19 Disease controls = 82 (GBS, CIDP, HSP)		

t2.19 **Table 2** (continued)

First author (type of study)	Controls	Patients	Diagnostic/prognostic value of blood NFL	Notes
t2.19 Feneberg, 2018 (cross-sectional study)		ALS onset ≤ 6 months = 54 ALS onset > 6 months = 135 Other MNDs (PLS, SMA, Kennedy disease) = 21 ALS mimics = 27 Neurologic disease controls = 60	- ALS patients with serum NFL in the mid-tertile had a HR = 4.47 (95% CI 1.08–18.63) vs patients with serum NFL in the low tertile - Serum NFL in differentiating early ALS vs neurologic disease controls, AUROC = 0.92 (95% CI 0.85–0.99, cutoff = 128 pg/mL) - Early ALS vs MND mimics, AUROC = 0.99 (95% CI 0.97–1, cutoff = 97 pg/mL) - Late ALS vs neurologic disease controls, AUROC = 0.9 (95% CI 0.83–0.97, cutoff = 116 pg/mL) - Late ALS vs MND mimics, AUROC = 0.97 (95% CI 0.94–1, cutoff = 95 pg/mL) High NFL concentrations were associated with shorter survival (at least a 6-month follow-up) [numbers are not reported]	- A minimum 3-month follow-up - Serum NFL concentrations were not significantly different between early and later symptomatic phases
t2.20 Steinacker, 2016 (longitudinal study)	HC = 28	ALS = 125		- Patients were subgrouped according to the progression rate at first examination into slow, intermediate, and fast progressors. - Blood NFL measures were taken every 6 months up to 3 years of follow-up and were stable over time
t2.21 Lu, 2015 (longitudinal study)	HC = 78 (London cohort = 42; Oxford cohort = 36)	ALS = 167 (London cohort = 103; Oxford cohort = 64)	- Serum NFL in differentiating ALS vs HC, AUROC = 0.86, at a cutoff level of 36 pg/mL (Oxford cohort) - Plasma NFL in differentiating ALS vs HC, AUROC = 0.87, at a cutoff level of 36.2 pg/mL (London cohort) - Patients with serum NFL (Oxford cohort) in the highest tertile had a HR = 6.05 (95% CI 1.68–21.87). - Patients with plasma NFL (London cohort) in the highest tertile had a HR = 3.78 (95% CI 1.68–8.50). - Patients with serum NFL (Oxford cohort) in the middle tertile had a HR = 2.68 (95% CI 0.87–8.27). - Patients with plasma NFL (London cohort) in the middle tertile had a HR = 1.91 (95% CI 0.86–4.23). - Patients with combined blood NFL in the highest tertile had a HR = 3.82 (95% CI 1.98–7.39). - Patients with combined blood NFL in the middle tertile had a HR = 2.08 (95% CI 1.09–3.97) Serum NFL in differentiating ALS vs HC, with sensitivity of 91.3% and specificity of 91% at a cutoff level of 26.6 pg/mL	- Multicenter study (2 cohorts) - Authors also conducted analyses of the 2 cohorts combined, using the corresponding NFL data (serum or plasma) from each cohort, using cohort-specific tertile cutoff levels, and adjusting Cox regression and Kaplan–Meier survival analyses by center
t2.22 Gaiotino 2013 (cross-sectional study)	HC = 67	ALS = 46 AD = 20 GBS = 19		- Neurological control patients consisted of patients suffered from tension-type headache (n = 21), lower back pain (n = 7), psychiatric

Table 2 (continued)

	First author (type of study)	Controls	Patients	Diagnosis/prognostic value of blood NFL	Notes
t2.23	Parkinsonian syndromes and degenerative ataxias		Neurological control patients = 68		disorders ($n = 26$), or miscellaneous non-specific symptoms for which no neurological explanation could be found ($n = 14$)
t2.24	Oosterveld, 2020 (cross-sectional study)	HC = 52	PD = 139	Serum NFL in differentiating PD vs HC, AUROC = 0.64 (95% CI 0.55–0.73), at the cutoff value of 15.6 pg/mL	- The inclusion of serum NFL in a panel of CSF biomarkers (phosphorylated α -synuclein/total α -synuclein ratio and oligomeric α -synuclein/total α -synuclein ratio) yielded a sensitivity of 91% and a specificity of 81% (AUC 0.90, 95% CI 0.83–0.97)
t2.25	Ng, 2020 (longitudinal study)	HC = 50	PD = 149 (76 PD patients, 30 TD and 46 PIGD, had plasma NFL measured at the 2-year mark)	- Baseline plasma NFL in differentiating PD vs HC, AUROC = 0.83 (95% CI 0.77–0.89) - At year 2, plasma NFL in discriminating TD subtype vs PIGD subtype, AUROC = 0.65 (95% CI 0.53–0.77)	- Participants were included in the Early Parkinson's Disease Longitudinal Singapore Study which is an ongoing prospective cohort study analyzing the progression of early PD over a follow-up period of 5 years. - PD patients were classified into motor subtypes of "tremor dominant" (TD), "postural instability and gait disorders" (PIGD), or "indeterminate" based on MDS-UPDRS part II and III components
t2.26	Marques, 2019 (cross-sectional study)	HC = 53	PD = 55 AP (MSA = 22, PSP = 7) = 29	- Serum NFL in differentiating AP vs PD, AUROC = 0.91 (95% CI 0.83–0.98), at the cutoff value of 14.8 ng/L - AP vs HC, AUROC = 0.88 (95% CI 0.80–0.96), at the cutoff value of 13.6 ng/L	- Patients were recruited when the clinical diagnosis was still uncertain; definite clinical diagnosis was established after 3 years of follow-up and updated again after a maximum of 12 years of follow-up data
t2.27	Li, 2019 (cross-sectional study)	HC = 100 consisting of 2 cohorts: - Cohort A = 9 - Cohort B = 91	Manifest SCA-3 = 107, consisting of 2 cohorts: - Cohort A = 17 - Cohort B = 90 Preclinical SCA-3 = 26 (all included in the cohort B)	- Serum NFL in differentiating manifest SCA-3 vs HC, AUROC = 0.98 (95% CI 0.96–1.00), at the cutoff value of 20 pg/mL - Preclinical SCA-3 vs HC, AUROC = 0.83 (95% CI 0.72–0.95), at the cutoff value of 10 pg/mL	- Participants in cohort B were classified into 3 subgroups according to the SARA scores: 26 preclinical SCA-3 individuals, 46 stage 1 SCA-3 patients, and 44 stage 2 SCA-3 patients
t2.28	Lin, 2019 (longitudinal study)	HC = 40	PD = 116 MSA = 22	- Plasma NFL in differentiating MSA vs PD, AUROC = 0.80, at the cutoff value of 24.06 pg/mL - PD vs HC, AUROC = 0.75, at the cutoff value of 12.34 pg/mL - Higher baseline NFL levels were associated with a higher risk of motor symptom progression (adjusted HR 1.03, 95% CI 1.01–1.07) and cognition progression (adjusted HR 1.03, 95% CI 1.01–1.05)	- PD patients with baseline NFL levels > 21.84 pg/mL were at higher risk of motor symptom progression. - PD patients with baseline NFL levels > 18.34 pg/mL were at higher risk of cognitive decline

Table 2 (continued)

First author (type of study)	Controls	Patients	Diagnostic/prognostic value of blood NFL	Notes
t2.29 t2.30 Donker Kaat, 2018 (longitudinal study)	HC = 95	PSP = 131	- Serum NFL in differentiating PSP vs HC, AUROC = 0.87 (95% CI 0.83–0.92), at the cutoff value of 38.3 pg/mL - Higher NFL levels were associated with reduced survival (adjusted HR 1.5, 95% CI 1.1–1.9)	- Diagnosis of PSP was made according to NINDS-SPSP criteria (2003–2014); 23 patients had pathological confirmation
t2.31 Wilke, 2018 (cross-sectional study)	HC = 45	c-MSA = 25 SAOA = 25 SCA = 20	- Serum NFL in differentiating c-MSA vs SAOA, AUROC = 0.74 (95% CI 0.59–0.89) - SCA vs HC, AUROC = 0.91 (95% CI 0.81–1.00)	- SCA patients consisted of SCA-1 ($n = 6$), SCA-2 ($n = 3$), SCA-3 ($n = 8$), and SCA-6 ($n = 3$)
t2.32 Hansson, 2017 (longitudinal study)	- Lund cohort HC = 53 - London cohort HC = 26	- Lund cohort PD = 171 - Lund cohort AP = 54 (MSA = 30, PSP = 19, CBD = 5) - London cohort PD = 20 - London cohort AP = 71 (MSA = 30, PSP = 29, CBD = 12) - Early-stage disease cohort PD = 53 - Early-stage disease cohort AP = 56 (MSA = 28, PSP = 22, CBD = 6)	- Blood NFL in differentiating PD vs AP, AUROC = 0.91 (95% CI 0.87–0.95) (Lund cohort) - PD vs AP, AUROC = 0.85 (95% CI 0.72–0.98) (London cohort) - PD vs AP, AUROC = 0.81 (95% CI 0.73–0.90) (early-stage disease cohort)	- The study included 2 independent prospective cohorts of PD and AP patients and HC: the Lund ($n = 278$) and London ($n = 117$) cohorts. - The third cohort consisted of PD and AP patients with a disease duration < 3 years (early-stage disease cohort, $n = 109$)
t2.33 HD				
t2.34 Byrne, 2018 (cross-sectional study)	HC = 20	HTT mutation carriers (premanifest HD = 20; manifest HD = 40) = 60	- Plasma NFL in differentiating HTT mutation carriers vs HC, AUROC = 0.91 (95% CI 0.85–0.97) - Plasma NFL in differentiating premanifest HD vs manifest HD, AUROC = 0.93 (95% CI 0.86–0.99)	- Participants were enrolled in the TRACK-HD* study. - At enrolment, participants with <i>HTT</i> CAG expansion mutations were classified as having premanifest or manifest HD based on the UHDRS-TMS.
t2.35 Byrne, 2017 (longitudinal study)	HC = 97	HTT mutation carriers (premanifest HD = 104, manifest HD = 97) = 201 They were divided into: - Early premanifest HD = 58 - Late premanifest HD = 46 - Manifest HD stage 1 = 66 - Manifest HD stage 2 = 31	Higher baseline plasma NFL levels in premanifest HD were associated with clinical disease onset during the 3-year follow-up period, adjusted HR 3.03, 95% CI 1.07–8.60	- 18 (17%) subjects with premanifest disease at baseline were newly diagnosed as having manifest HD during the 3 years of follow-up
t2.36 CJD				
t2.37 Staffaroni et al., 2019 (longitudinal study)		sCJD = 188	Higher baseline levels of plasma NFL levels were associated with shorter survival, HR 2.08 (95% CI 1.22–3.54)	Participants included patients with probable and definite (pathology-proven) sCJD with PRNP codon 129 polymorphism data available

Table 2 (continued)

	First author (type of study)	Controls	Patients	Diagnostic/prognostic value of blood NFL	Notes
t2.39	Thompson, 2018 (cross-sectional study)	HC = 24	sCJD = 45	Serum NFL in differentiating sCJD vs HC, AUROC = 1.0	- The present study included 132 autopsy cases with rapidly progressive neurological syndromes.
t2.40	Kovacs, 2017 (cross-sectional study)	HC = 18	sCJD = 65 gCJD = 21 AD = 21 Other neurological pathologies = 25	- Plasma NFL in differentiating sCJD vs HC, AUROC = 0.99 (95% CI 0.98–1.0) - gCJD vs HC, AUROC = 1.0 (CI 1.0–1.0) - AD vs HC, AUROC = 0.99 (95% CI 0.97–1.0) - Other neurological disorders vs HC, AUROC = 0.96 (CI 0.90–1.0)	- Cases with a wide range of neuropathological alterations, including cerebrovascular disease, inflammation (meningoencephalitis), primary age-related tauopathy, non-AD tauopathies or Lewy body pathology
t2.41	Steinacker, 2016 (cross-sectional study)	HC = 40	sCJD = 33 gCJD = 9 GSS mutation carrier = 1 Demented controls (DCo) = 20	Serum NFL in differentiating sCJD + gCJD vs HC + DCo, AUROC = 0.95	- 39 CJD diagnoses were neuropathologically verified. - Patients with other diseases included AD (n = 12), MCI (n = 4), FTD (n = 3), and NPH (n = 1)

Aβ42 amyloid β-peptide 1–42; *AD* Alzheimer’s disease; *ADNI* Alzheimer’s Disease Neuroimaging Initiative; *ALS* amyotrophic lateral sclerosis; *AP* atypical parkinsonism; *APOE* apolipoprotein E; *AUROC* area under the receiver operating curve; *bvFTD* behavioral variant of frontotemporal dementia; *c-MSA* cerebellar variant MSA; *CBd* corticobasal degeneration; *CDR* cognitive dementia rating; *CI* confidential interval; *CIDP* chronic inflammatory demyelinating polyneuropathy; *CJD* Creutzfeldt–Jakob disease; *CSF* cerebrospinal fluid; *C9ORF72* chromosome 9 open reading frame 72; *DLB* dementia with Lewy body; *FTD* frontotemporal dementia; *FTD-MND* frontotemporal dementia with *ALS*; *gCJD* genetic Creutzfeldt–Jakob disease; *GBS* Guillain-Barre syndrome; *GENFI* genetic FTD initiative; *GSS* Gerstmann–Strausler–Scheinker disease; *GRN* progranulin; *HC* healthy controls; *HR* hazard ratio; *HSP* hereditary spastic paraplegia; *HTT* huntingtin; *hPPA* logopenic variant PPA; *MAPT* microtubule-associated protein tau; *MCI* mild cognitive impairment; *MCI-AD* MCI converters to AD; *MDS-UPDRS* Movement Disorder Society–Unified Parkinson’s Disease Rating Scale; *MND* motor neuron disease; *MSA* multiple system atrophy; *NFL* neurofilament light chain; *nvPPA* non-fluent variant PPA; *NINDS-SPSP* National Institute of Neurological Disorders and Stroke and the Society for PSP; *NPH* normal-pressure hydrocephalus; *PD* Parkinson’s disease; *PLS* primary lateral sclerosis; *PPA* primary progressive aphasia; *PMA* primary muscular atrophy; *PPD* primary psychiatric disorders; *PRNP* prion protein; *PSP* progressive supranuclear palsy; *p-tau* phospho-tau; *sCJD* sporadic Creutzfeldt–Jakob disease; *SAOA* sporadic adult-onset ataxia; *SARA* Scale for the Assessment and Rating of Ataxia; *SCA* spinocerebellar ataxia; *SMA* spinal muscular atrophy; *svPPA* semantic variant PPA; *UHDRS* Unified Huntington’s Disease Rating Scale–Total Motor Score

*TRACK-HD is a multinational prospective observational study of HD that examines clinical and biological findings of disease progression in individuals with premanifest HD and early-stage HD

216 **NFL as Staging and Prognostic Biomarker**

217 Studies in AD and MCI-AD patients found a correlation
218 between plasma NFL concentration and cognitive impair-
219 ment, MRI hippocampal volume loss and brain atrophy,
220 and cerebral ¹⁸F-FDG-PET hypometabolism [76, 81–87].
221 Moreover, higher plasma NFL levels predicted faster cog-
222 nitive deterioration and a higher rate of brain atrophy and
223 hypometabolism in MCI patients over time [77]. Baseline
224 plasma and CSF NFL levels were similarly associated with
225 short-term declines in imaging measures of neurodegenera-
226 tion and with global cognitive worsening, but not with
227 change in amyloid ligand retention on PET [35], differently
228 from CSF t-tau concentration that critically depends on ce-
229 rebral Aβ burden [88]. Instead, increased plasma NFL was
230 related to baseline and longitudinal glucose hypometabolism,
231 which is an unspecific neurodegeneration marker, in AD-
232 related regions of MCI Aβ+ individuals [87].

233 In a longitudinal analysis of NFL plasma levels in a
234 large cohort of subjects enrolled in the Alzheimer’s
235 Disease Neuroimaging Initiative (ADNI), Mattsson and
236 colleagues [82] found increasing rates of NFL changes
237 from preclinical AD stage to frank AD dementia through
238 prodromal phase, suggesting NFL as a dynamic biomarker
239 sensitive to AD disease progression. Of note, longitudinal
240 NFL variations correlated with several baseline AD-related
241 features (CSF biomarkers, imaging measures, and cogni-
242 tion) in the whole population, though with significant dif-
243 ferences regarding clinical stage. Actually, the strictest as-
244 sociations were reported in MCI participants. Longitudinal
245 NFL level was generally increased in patients who were
246 classified as N+ (using temporal brain atrophy as N– indi-
247 cator) and in those who were only T+. Therefore, NFL
248 might reflect a neurodegenerative process that occurred
249 independently from Aβ pathology. Noteworthy, the NFL
250 rate of change, rather than NFL absolute concentration,
251 was subject to a significant increase in mutation carriers
252 compared with non-carriers. Moreover, the NFL rate of
253 change strongly correlated with longitudinal precuneus
254 cortical thinning in both symptomatic and presymptomatic
255 mutation carriers [89].

256 **NFL as Risk/Screening Biomarker**

257 Blood NFL levels seem to predict the progression to AD de-
258 mentia in patients with subjective memory complaints [77].
259 An association between regional hypometabolism in the right
260 hippocampus and higher plasma NFL levels was reported in
261 cognitively normal participants from the ADNI database [87].
262 Hu and colleagues [90] explored the predictive role to develop
263 AD of plasma NFL at the preclinical stage. Interestingly, plas-
264 ma NFL concentrations were already abnormally high in cog-
265 nitively normal individuals with significant Aβ-related

pathological changes. Baseline plasma NFL levels did not
differ in normal elderly volunteers who remain cognitively
intact during the follow-up, independently from an initial am-
yloid PET positivity status. Instead, a trend toward elevated
plasma NFL concentration was observed in Aβ+ individuals
with subjective memory complaints compared to subjects
without memory complaints who were Aβ+, and plasma
NFL resulted to be inversely associated with cognitive perfor-
mance [91]. By contrast, other groups investigated the corre-
lation between serum NFL levels with cerebral metabolism in
MCI patients. Regional hypometabolism in bilateral
parahippocampal gyri, right fusiform, and middle temporal
gyri was independently predicted by plasma NFL [92].

Weston and colleagues [93] reported increased serum NFL
concentrations also in symptomatic and presymptomatic fa-
miliar AD (FAD) mutation carriers, showing a significant cor-
relation with the estimated years to/from symptom onset
across all mutation carriers as well as with cognitive decline
and MRI atrophy. This finding suggests that increases in se-
rum NFL precede the onset of AD symptoms. A large study in
the DIAN cohort confirmed NFL as a sensitive marker of
early neurodegeneration, finding significant increased serum
NFL levels in AD mutation carriers (Aβ precursor protein
(APP) or presenilin 1 (PSEN1) or presenilin 2 (PSEN2))
16 years before disease onset [89]. The rate of change of
serum NFL peaked in mutation carriers during the conversion
phase to clinically evident cognitive impairment and reached a
plateau in symptomatic carriers; absolute values of NFL
showed a trend toward a slow increase over time (Table 2).
Interestingly, the increase in plasma NFL concentration dur-
ing the follow-up (15–30 months) in 79 elderly participants
without dementia, including 15 subjects with MCI, was asso-
ciated with a significant decline in both attention and global
cognition and with an increase in cerebral amyloid PET up-
take [32]. More recently, baseline serum NFL was shown to
be a strong and independent predictor of brain volume loss
and subtle cognitive changes in a longitudinal study cohort of
neurologically intact individuals [79].

NFL as Predictive Biomarker

Although not yet in humans, transgenic mice models treated
with a β-secretase (BACE) inhibitor showed beneficial effects
on AD-relevant downstream markers, including reduced plas-
ma NFL concentrations [30].

FTD

The term FTD indicates a heterogeneous spectrum of NDDs
inexorably conveying to a dementia syndrome characterized by
predominant behavioral—behavioral FTD (bvFTD) [94]—or
language—primary progressive aphasia (PPA) [58]—

impairment. It is the third most common neurodegenerative dementia after AD and DLB and is typically diagnosed in middle age [95]. bvFTD is the most prevalent phenotype (55–60% of cases) whereas PPA (40–45% of cases) can be further classified as non-fluent/agrammatic variant (nfvFTD) and semantic variant (svFTD) [96]. Notably, an additional clinical PPA variant, named logopenic variant, can show AD pathological features in more than half of subjects [97]. Finally, a clinical overlap between FTD and ALS is described and about 10–15% of cases with ALS report a dementia syndrome in the FTD spectrum (ALS-FTD) [98]. The underlying pathologies in FTD, essentially abnormal accumulations of either tau or TAR DNA-binding protein 43 (TDP-43) proteins, may be recognized only on postmortem examination. These misfolded protein aggregates lead to atrophy (structural MRI) and hypometabolism (^{18}F FDG-PET) of frontal and/or anterior temporal lobes depending on phenotype [41].

Unfortunately, with the exception of causative mutations in genetic forms (about 10% of cases: hexanucleotide repeat expansions near the chromosome 9 open reading frame gene (C9orf72), progranulin (GRN), and microtubule-associated protein tau (MAPT) [99]), CSF poly(GP) detection in C9ORF72 expansion carriers, and decreased CSF/blood progranulin levels in GRN mutation carriers, specific pathophysiological biomarkers for FTD are completely lacking. However, the diagnosis of FTD remains very challenging, especially for behavioral variant as its diagnosis is mainly based on clinical assessment and because its symptoms show a significant overlap with primary psychiatric disorders [100].

In this context, blood NFL is a promising candidate biomarker for FTD, especially for disease differential diagnosis, monitoring, and prognosis [101, 102]. Recent evidence proved that blood and CSF levels of NFL are tightly related and significantly higher in FTD subjects than in HC [103], without gender differences [104]. Furthermore, although NFL levels generally increase with aging, this association seems not present for FTD patients [16, 105–107]. Blood NFL levels tightly correlate with CSF values in almost all studies measuring this biomarker in both fluids, thus suggesting that the peripheral concentrations of NFL substantially reflect the pathophysiological modification within CNS leading to NFL increase in CSF.

NFL as Diagnostic Biomarker

Serum NFL levels distinguished FTD patients from controls with good/optimal diagnostic accuracy (Table 2) [105, 108–110]. Interestingly, this biomarker was higher in bvFTD individuals in comparison with psychiatric patients affected by depression, schizophrenia, and bipolar disorders [106], in which bvFTD misdiagnosis is common [100]. The diagnostic accuracy to differentiate bvFTD from psychiatric disorders was

above 80% (Table 2), independently from the specific psychiatric condition (mood or psychotic disorders) [106, 107].

Only one study compared both FTD and AD subjects, reporting that serum NFL levels were higher in bvFTD patients [109], and separated the two groups with a sensitivity and specificity of 93% and 61%, respectively (Table 2), after a preliminary exclusion of bvFTD patients with an AD biomarker profile and clinical AD subjects without a core biomarker confirmation. Moreover, serum NFL concentrations seemed to be higher in nfvPPA and svPPA than lvPPA subjects [105], though with only moderate accuracy. A further study showed no significant differences between PPA subtypes [110].

Finally, although FTD individuals had higher serum NFL levels than subjects with other cognitive disorders such as AD, ALS patients reported even more elevated concentration [108]. Notably, ALS subjects present a TDP-43 pathology in about 95% of cases, suggesting a potential association between increased NFL concentration and TDP-43 pathology. Further confirmation of this hypothesis is supported by observing that FTD forms expected to be TDP-43 positive (C9ORF72 and GRN mutation carriers, or svPPA phenotype) reported higher concentration of this biomarker than FTD subtypes expected to be tau positive (MAPT mutation carriers and nfvPPA) [16, 99, 104].

NFL as Staging and Prognostic Biomarker

In different studies, serum NFL increases overtime in FTD subjects, independently from the phenotypes, with the exception of lvPPA [105, 109]. A longitudinal Mini-Mental State Examination (MMSE) decline was correlated with baseline serum NFL levels [107]. Disease duration was not associated with NFL concentration although one study reported a poor survival in FTD subjects in the higher tertile of serum NFL levels (Table 2).

Additionally, peripheral blood NFL concentrations appeared to reflect specific regional brain atrophy related to clinical phenotypes (PPAs or bvFTD). In bvFTD patients, serum NFL was associated with a low cognitive score and a reduction in whole-brain volume and was correlated with brain atrophy, including frontal and subcortical regions [99, 104, 109, 110].

Serum NFL was correlated with baseline cognitive impairment, cognitive decline overtime, and atrophy progression of the left frontal lobe and the right middle frontal gyrus in PPA individuals and nfvPPA/svPPA subjects, respectively [105, 107]. On the other hand, although only in one study, serum NFL concentration was not related to specific hypometabolic regions on ^{18}F FDG-PET in PPA subjects [110].

NFL as Risk/Screening Biomarker

Noteworthy, serum NFL was higher in genetic FTD with a full-blown clinical picture but not in presymptomatic carriers

compared to HC, independently from the gene mutation. Moreover, it was consistently higher in converters than in non-converter carriers [104] and increased overtime in converters but not in symptomatic FTD as well as non-converters. Therefore, serum NFL could differentiate genetic FTD patients from presymptomatic carriers, with an excellent diagnostic accuracy (Table 2) [16]. By contrast, the discriminatory accuracy of the biomarker relative to presymptomatic genetic carriers and controls resulted quite poor (Table 2).

ALS

ALS is a progressive neurological disease in which upper motor neuron (UMN) and lower motor neuron (LMN) degenerate, leading to paralysis and death, typically within 3–5 years from symptom onset. To date, there is no definitive diagnostic test for ALS, and confirmation of diagnosis is based on clinical findings, electromyography results, and exclusion of mimics [52]. Despite efforts to increase the sensitivity of diagnostic criteria, often the diagnosis is made only after the onset of symptoms for both sporadic and familial ALS [111, 112]. An early diagnosis would be paramount, since it was observed that the benefit of riluzole is related to its early administration.

A large body of research exists on neurochemical ALS biomarkers [113, 114], among which phosphorylated neurofilament heavy chain (pNFH) and NFL have been postulated as the most interesting candidates [115, 116]. This is not surprising, given the axonal impairment that characterizes the disease already at the early stage, with a large release of NF in CSF [117]. Additionally, previous studies indicate cytoskeletal proteins as one of the key factors contributing to neurodegeneration in ALS [118–123]. Other evidences provide additional support that NFL aggregation is an early event in motor neuron disease [124], and that NFL is involved in the aggregation and neurotoxicity of other proteins in motor neurons [125]. At the same time, elevated NFL levels in ALS may be explained by the higher content of axonal proteins in motor neurons compared to other neuronal populations [126]. Nonetheless, several data highlighted that NFL is able to discriminate ALS patients from healthy and disease controls [14, 117, 127, 128], especially in cases with predominant UMN signs, and correlates with clinical disability [129], disease stage, progression, and/or prognosis [130, 131], probably reflecting the burden of motor neuron degeneration. Although CSF NFL remains the more robust fluid biomarker for ALS because of its directly reflecting alterations in the CNS, a high correlation between CSF and blood NFL concentrations has been reported [132]. Moreover, at odds with other neurodegenerative diseases such AD, NFL concentrations do not correlate with age in ALS individuals [133–135].

NFL as Diagnostic Biomarker

Mounting evidence reports significantly higher blood NFL levels in ALS patients when compared to controls (Table 2) [40, 135–138]. The diagnostic performance of serum NFL in discriminating ALS and non-neurodegenerative subjects showed excellent sensitivity and specificity (Table 2) [139, 140]. These findings led authors to propose the introduction of serum NFL measurement into clinical practice as supportive diagnostic tool. In addition, serum NFL showed significantly elevated concentration in ALS even at the onset of the first symptoms, confirming its potential role as a biomarker for early detection of symptomatic sporadic ALS. In this regard, serum NFL concentrations demonstrated optimal sensitivity and specificity also in distinguishing early symptomatic ALS from other neurologic diseases or motor neuron disease mimics, independently whether diagnosis was definite, probable, or possible, following the El Escorial criteria (Table 2) [134]. Interestingly, Gille and colleagues [135] reported an increase of serum NFL as a function of the number of regions (i.e., cranial, cervical) affected by UMN degeneration. Accordingly, in a MRI-based study, elevated CSF and serum NFL concentrations were significantly associated with lower diffusion tensor imaging (DTI) fractional anisotropy and increased radial diffusivity in the corticospinal tract of ALS patients, as well as with clinically UMN score burden [133]. On the other hand, previous studies have shown that NFL levels were not increased in Kennedy disease and spinal muscular atrophy (strictly LMN diseases) [128, 134]. As a consequence, a subclinical involvement of the UMN is likely in ALS patients with isolated LMN symptoms and elevated serum NFL concentration [117]. However, the neuroanatomical correlate of NFL increase is not yet clear since Verde and colleagues [139] showed a lack of association with DTI-MRI measurements of the integrity of cerebral white matter tracts in the brain of ALS patients. Finally, serum NFL levels were reported relatively lower in patients with primary lateral sclerosis (PLS) and hereditary spastic paraplegia (HSP), two UMN-isolated syndromes, compared with ALS subjects, suggesting in such patients different pathophysiological processes and rates of neurodegenerative diseases [134, 135].

NFL as Staging and Prognostic Biomarker

Several studies reported that blood NFL levels correlate with disease severity parameters, such as the decline in the ALS Functional Rating Scale-Revised (ALSFRS-R) score and the ALS Milano-Torino Staging (MITOS) system score [135, 137, 140, 141]. Furthermore, serum NFL levels at recruitment or at the time of diagnosis predicted survival independently from other clinical variables and were negatively associated with disease duration (Table 2) [136, 138, 142]. Thouvenot and colleagues

[140] evaluated the largest series ever of serum samples taken from ALS patients, finding that NFL concentration was the most important parameter related to ALS survival in multivariate models (Table 2). Likewise, serum NFL concentrations in the middle and high tertile were associated with an increased HR compared with those of patients in the lowest tertile (Table 2) [135]. Interestingly, unlike pNFB, NFL levels seem to change minimally throughout the course of the disease, maintaining distinct temporal profiles from controls, and a steady trajectory [136].

However, not all studies confirmed blood NFL as a robust prognostic biomarker in ALS patients, even if all proved lower NFL concentration in slow disease progressors [141]. Notably, the ALSFRS-R and the ALS MITOS system better correlated with CSF than serum at the baseline [137]. No significant correlation has been found between blood NFL levels and cognitive dysfunction in ALS [135].

NFL as Risk/Screening Biomarker

In contrast with AD, CSF and blood NFL levels are reported normal in presymptomatic ALS mutation carriers (C9orf72, SOD1, FUS/TLS, or TARDBP), but they increase suddenly with symptom onset in symptomatic mutation carriers as demonstrated by Weydt and colleagues [143]. Furthermore, using the parental age of disease onset as a proxy for assumed age of clinical onset, any trend toward an increase of NFL concentration was observed in asymptomatic mutation carriers. Despite recent longitudinal data on a large cohort of presymptomatic, SOD1 mutation carriers provided evidence that an increase in CSF and blood NFL levels occurs at least 1 year before of any clinical manifestations of the disease [144].

NFL as Predictive Biomarker

It would be interesting to determine whether riluzole reduces blood NFL levels over time given its neuroprotective effects and, although minimally, its capacity to slow disease progression. Currently, no studies investigated blood NFL as an indicator of treatment response in ALS, and no difference in blood NFL levels between patients treated and not treated with riluzole has been reported so far [136, 139]. On the other hand, recent studies on spinal muscular atrophy (SMA), a group of severe autosomal recessively inherited neurodegenerative disorders characterized by degeneration of the spinal alpha motor neurons, have highlighted an emerging role of NFL in tracking disease progression and response to treatment. Of note, recent data provided evidence that CSF NFL levels normalize and correlate with motor improvement in children with SMA treated with nusinersen, with a greatest benefit found in children who received treatment earliest during the course of disease [145]. Nusinersen, an antisense oligonucleotide delivered intrathecally by a spinal tap, is the first drug clinically

approved for the treatment of all SMA types, with a rather dramatic impact on phenotype [146]. The levels of two additional biomarkers of neurodegeneration (CSF tau and glial fibrillary acidic protein (GFAP), an intermediate filament present in astrocytes) decreased together with CSF NFL after nusinersen administration, indicating that the neuronal and astroglia damage can be restored by nusinersen treatment [145]. Moreover, the decrease of NFL concentration was much larger than that of tau and GFAP, suggesting NFL as an early treatment response biomarker in SMA patients, helpful to select those patients will benefit to continue such an invasive treatment. Further studies with a long follow-up are needed, but these preliminary results in SMA indicated NFL as a promising marker for upcoming disease-modifying therapies in diseases beside SMA. Conversely, it is worth mentioning that the diagnostic and monitoring value of NFL in CSF and blood has not been confirmed in adolescent and adult SMA-type (SMA types 2 and 3) patients treated with nusinersen [134, 147]. It was hypothesized that NFL release is lower in late-onset SMA than in the infantile-onset subtype. Actually, the first phenotype is characterized by a long-lasting and chronic disease course while the foster by an acute and highly aggressive onset. Additionally, subjects with infantile-onset SMA report a significantly better response to nusinersen therapy when compared to individuals with adult-onset one. In this regard, the finding of normal blood levels of NFL in SMA could be used in a diagnostic panel of biochemical markers to help differentiate patients presenting with motor neuron deficits, separating SMA from ALS. Indeed, a substantial proportion of patients with SMA initially receive a diagnosis of ALS [148].

Degenerative Parkinsonisms

PD is the most common degenerative parkinsonism, with evidence of progressive loss of dopaminergic neurons in the pars compacta of the substantia nigra. Diagnostic criteria have been recently revised to improve diagnostic accuracy imaging biomarkers as supportive features [61]. However, early diagnosis and progression prediction remain challenging for physicians. Of note, the differential diagnosis between PD and AP can be difficult, mainly at the early clinical stage. Similarly, evolution of diagnostic criteria for AP improved accuracy, but misdiagnosis rates are still high [149–152]. The APs that most commonly mimic PD are progressive supranuclear palsy (PSP) and multiple system atrophy (MSA), whereas among APs, the lowest diagnostic accuracy regards the corticobasal degeneration (CBD).

Currently, biochemical biomarkers for PD and AP are an unmet need, but many CSF/serum molecules are under evaluation. CSF NFL concentration overlaps in patients with PD, PD with dementia (PDD), and DLB and are comparable with

those in HC [31]. In contrast, it has been demonstrated that CSF NFL levels are markedly increased in AP patients. Accordingly, it might discriminate between PD and AP with a high degree of diagnostic accuracy [17, 18, 153, 154]. This is in line with the remarkable axonal degeneration of large myelinated axons occurring in AP as well as with the rapid neuronal loss in such conditions [155]. Furthermore, CSF NFL concentration correlates with measures of disease severity and other clinical variables, demonstrating its capability to reflect neurodegenerative mechanisms. However, to overcome the well-known limits related to CSF examination, blood-derived NFL would be a more favorable biomarker. In this regard, the strong correlation between blood and CSF NFL levels in parkinsonian syndromes holds potential for an application in clinical practice [156].

PD

NFL as Diagnostic Biomarker

Similar to CSF results, NFL concentration in serum/plasma is considered useful for a differential diagnosis between PD and AP [157]. This has been tested for the first time in three independent prospective cohorts of PD, PSP, MSA, and CBD patients, compared with HC. Blood NFL levels in AP were significantly elevated compared with those in PD, showing a diagnostic accuracy ranging from good (in the early cohort with disease duration < 3 years) to excellent (in the Lund cohort) (Table 2) [156]. Conversely, blood NFL levels were not able to accurately separate PD from HC. A subsequent study in subjects with an uncertain diagnosis at the time of inclusion confirmed similar results (Table 2) [158]. Nevertheless, recent studies support the promise of plasma NFL as a diagnostic biomarker also in PD, demonstrating relatively higher NFL levels in cases vs controls [159] and a good diagnostic accuracy in differentiating PD patients from HC (Table 2) [160]. Moreover, higher serum NFL levels were found even at early stages of the disease and in participants at risk of disease progression (prodromal PD and symptomatic and asymptomatic mutation carriers of known PD genetic mutations), indicating the presence of active disease and potential for conversion to either PD or parkinsonian syndromes [161].

NFL as Staging and Prognostic Biomarker

Heterogeneous results regarding possible correlations between blood NFL and PD clinical features in three independent PD cohorts have been provided in the prospective and longitudinal study of Hansson and colleagues [156]. In general, higher blood NFL levels were observed in more advanced PD and, in the Lund PD cohort, a higher blood NFL concentration was associated with disease duration and more

severe motor symptoms (measured as Hoehn and Yahr (H&Y) stage, Unified Parkinson's Disease Rating Scale (UPDRS) III motor score, Timed Up and Go Test, and Tandem Gait Test). Conversely, no clinical correlations were described in the London cohort and the early-stage disease cohort [156]. However, further studies confirmed the positive relation between plasma NFL levels and motor symptom severity (measured as H&Y stage and UPDRS part III score) and proved a significant correlation between plasma NFL concentration and cognitive dysfunction at MMSE [161, 162]. In another study, PDD patients reported higher plasma NFL level compared with PD subjects without dementia [84], supporting an association between plasma NFL and cognitive function in PD patients [84]. Furthermore, higher baseline plasma NFL concentrations in PD patients were found to be longitudinally associated with a higher risk of progression for both motor and cognitive symptoms, suggesting that serum NFL may be a biomarker of clinical progression in PD (Table 2) [160–162].

PSP

NFL as Diagnostic Biomarker

Two other studies confirmed the diagnostic value of blood NFL in PSP patients showing good capability to discriminate between PSP and HC (Table 2) [163, 164]. In contrast, blood NFL is not suitable to separate PSP from other forms of AP [156] and similar levels are reported in patients with MSA and PSP [158].

NFL as Staging and Prognostic Biomarker

Greater baseline NFL levels in serum/plasma seem to correlate with disease severity and clinical progression in PSP patients, though with conflicting results. Such heterogeneity may reflect differences in study design, since PSP patients have been evaluated as a separate group in some studies but not in others where PSP, MSA, and CBD patients have been combined as a whole group. Specifically, blood NFL levels positively correlated with motor symptom severity, evaluated as H&Y stage and with UPDRS III motor score, but not with disease duration or other clinical assessments, in the AP group (including also MSA and CBD patients) [156]. Similarly, serum NFL concentration at baseline correlated with motor performances, measured with the International Cooperative Ataxia Rating Scale score and Tandem Gait Test in another cohort of AP patients including PSP [158].

In studies focusing exclusively on PSP patients, higher serum NFL levels were related to more severe motor, functional, and cognitive disability as well as shorter survival but not with age at symptom onset or disease duration (Table 2) [163]. Notably, NFL levels in the higher tertile were

705 associated with worse survival (Table 2) [164]. Higher base-
 706 line plasma NFL levels also predicted greater whole-brain
 707 and superior cerebellar peduncle volume loss at 1-year fol-
 708 low-up [163].

709 **MSA and Degenerative Ataxias**

710 **NFL as Diagnostic Biomarker**

711 As for PSP, studies indicate elevated blood NFL concentration
 712 in MSA patients, suggesting its use in discrimination of MSA
 713 from PD and HC with a good diagnostic accuracy (Table 2).
 714 However, as aforementioned, NFL cannot discriminate
 715 among APs [158].

716 Moreover, blood NFL was proposed to improve the differ-
 717 ential diagnosis of degenerative ataxias. In a pilot study eval-
 718 uating serum NFL levels in patients with a clinical diagnosis
 719 of probable cerebellar-MSA (c-MSA) subtype, sporadic adult-
 720 onset ataxia (SAOA), and frequent repeat-expansion
 721 spinocerebellar ataxias (SCAs 1, 2, 3, and 6) and in HCs,
 722 serum NFL concentration was found to be higher in SCA
 723 patients and in the c-MSA group compared with controls.
 724 This is probably the result of the diffuse involvement of
 725 spinocerebellar and corticospinal tracts in these multisystemic
 726 neurodegenerative ataxias [165]. However, the performance
 727 of serum NFL differentiating c-MSA from SCAOA was only
 728 moderate (Table 2), in contrast with a higher accuracy previ-
 729 ously reported for CSF NFL (AUC = 0.93) [166]. NFL levels
 730 were significantly lower in SCAOA and comparable with those
 731 of HC. A further study investigated serum NFL concentration
 732 in large cohorts of SCA-3 subjects and demonstrated higher
 733 levels in both preclinical and manifest SCA-3 individuals
 734 compared with HC [167]. Serum NFL levels discriminated
 735 manifest SCA-3 from HC with excellent accuracy, and the
 736 diagnostic performance remained good in distinguishing pre-
 737 clinical SCA-3 subjects from HC (Table 2) [167]. Recently,
 738 plasma NFL concentrations resulted higher also in patients
 739 affected by Friedreich's ataxia (FA), which is the most com-
 740 mon autosomal recessive ataxia caused by CAG repeat expan-
 741 sion in the ATXN3/MJD1 gene, compared with aged-
 742 matched controls [168].

743 **NFL as Staging and Prognostic Biomarker**

744 Serum NFL in c-MSA patients does not seem to correlate with
 745 clinical disease severity (as assessed by the Scale for the
 746 Assessment and Rating of Ataxia (SARA)) or disease progres-
 747 sion [165]. Similarly, a recent study in 99 patients with genet-
 748 ically confirmed FA did not find a correlation with disease
 749 severity (as defined by SARA score), age at onset, or disease
 750 duration [169]. Moreover, serum NFL concentration remains

stable in a subgroup of 14 FA patients who received a 2-year
 follow-up evaluation [169].

Conversely, serum NFL concentration increased with dis-
 ease severity in a large cohort of SCA-3 patients, including
 manifest and preclinical individuals, and correlated with both
 clinical scales (according to SARA and International
 Cooperative Ataxia Rating Scale (ICARS) scores) and reduc-
 tion of cerebellar and brainstem volume [167]. Preclinical
 SCA-3 group was divided in early and late preclinical sub-
 groups using the median predicted number of years to onset of
 manifest disease. Serum NFL concentrations resulted higher
 in manifest than preclinical SCA-3 subjects and in late pre-
 clinical SCA-3 subjects compared with early preclinical SCA-
 3 individuals. However, no differences were observed be-
 tween early preclinical subjects and HC [167]. Despite CAG
 repeat count is a well-known prognostic factor for SCA-3 and
 FA, a correlation between serum NFL and CAG repeat lengths
 has been inconsistently reported [168, 169].

769 **NFL as Risk/Screening Biomarker**

In their study on 133 SCA-3 patients, Li and colleagues [167]
 demonstrated higher serum NFL concentrations in 26 preclin-
 ical ATXN3 mutation carriers (patients with SARA score < 3)
 compared with controls. Moreover, a correlation between mo-
 tor symptoms, neuroimaging markers, and serum NFL was
 found in all ATXN3 mutation carriers, suggesting that NFL
 may serve to track neurodegeneration and disease progression
 already in pre and prodromal SCA-3 phases.

778 **HD**

Among the most common neurodegenerative diseases, HD is
 unique, since the major part ($\approx 99\%$) of individuals presenting
 a HD phenotype have a mutation in the same gene [170].
 Indeed, HD is an autosomal dominant inherited neurodegen-
 erative disease with the typical manifestations of involuntary
 movements, psychiatric symptoms, and cognitive decline.
 The etiological basis is the deleterious expansion of
 polyglutamine encoding CAG repeats in the huntingtin
 (HTT) gene, leading to the expression of neurotoxic mutant
 huntingtin (mHTT) and extensive degeneration of neurons
 primarily occurring in the striatum and cortex [171]. The dis-
 ease usually starts in midlife, with age of onset inversely cor-
 relating to CAG repeat number [171]. Although the cause is
 known, disease-modifying treatments are not yet available. In
 HD, a reliable genetic test confirms a clinical diagnosis in
 symptomatic people or predicts disease onset in asymptomatic
 mutation carriers [172]. As a consequence, a novel biomarker
 should be directed to track disease progression and predict a
 treatment response to targeted therapies. Although not conclu-
 sive, the results of the available studies display that blood NFL

799 could have a role in this context. Previous reports on CSF
800 NFL indicate elevated concentrations in HD subjects [19,
801 173, 174]. This is not surprising because mtHTT interacts with
802 other proteins altering their function and finally leading to
803 abnormal protein aggregation and impaired axonal transport
804 [175]. Furthermore, the level of misfolded mtHTT protein
805 correlates with NFL concentration in CSF, thus suggesting a
806 contemporary releasing of both proteins from damaged neu-
807 rons [176].

808 **NFL as Staging and Prognostic Biomarker**

809 In the first retrospective study investigating NFL concentra-
810 tions in the blood of premanifest HD (preHD) and early-stage
811 HD patients enrolled in the TRACK-HD cohort, Byrne and
812 colleagues [177] showed higher baseline NFL levels in 201
813 HTT mutation carriers, including 58 with early premanifest
814 and 46 subjects with late premanifest disease, than in controls.
815 Moreover, NFL concentration reflected baseline motor and
816 cognitive deficits in HD patients and differed significantly
817 with increasing disease stage. Positive associations were
818 found between plasma NFL concentration, age, and CAG
819 triplet repeat counts, with higher CAG lengths being associat-
820 ed with earlier and steeper increases in plasma NFL [177].
821 Therefore, NFL is the first biofluid marker showing a direct
822 relationship with a causative gene expansion [178].

823 Of note, baseline plasma NFL predicted rates of brain at-
824 rophy, cognitive decline, and worsening of functional ability
825 and motor performance in mtHTT carriers [177].
826 Interestingly, it was closely associated with the rate of
827 whole-brain atrophy than with the rate of striatal one, suggest-
828 ing that plasma NFL reflects more the rate of global neuronal
829 degeneration than that of a specific brain area [177].
830 Additionally, in the same TRACK-HD cohort, Johnson and
831 colleagues [179] showed voxel-wise region-specific associa-
832 tions between plasma NFL levels and both cross-sectional and
833 longitudinal MRI cortical thinning and white matter volume
834 reduction, highlighting the value of NFL as a dynamic and
835 robust marker of brain atrophy. Notably, higher concentra-
836 tions of NFL in plasma were associated with lower volume
837 in regions known to be affected in HD and predicted subse-
838 quent occipital gray matter atrophy and widespread white mat-
839 ter reduction over the 3-year follow-up, independently of age
840 and CAG length repeats [179]. NFL increased significantly
841 from baseline both in individuals with premanifest HD and
842 in those with manifest HD [179]. Remarkably, in a subsequent
843 study, Byrne and colleagues [180], combining CSF/plasma
844 NFL and CSF mutant huntingtin protein (mHTTp) as biofluid
845 biomarkers, demonstrated that NFL levels were more accurate
846 than mHTTp to discriminate between premanifest and mani-
847 fest HDs and correlated with severity of symptoms better than
848 mHTTp in manifest HD.

CJD

CJD is the most common human prion disease. Approximately 850
851 85% of cases are sCJD, but in a minority of cases, CJD can be
852 genetically determined (gCJD) [181]. The disease is a rapidly
853 progressive and fatal neurodegenerative condition, whose differ-
854 ent phenotypes depend, at least in part, by polymorphisms on
855 the gene encoding prion protein (PrP) [182]. Diagnosis is fre-
856 quently tardive and relies on clinical World Health Organization
857 (WHO) criteria supported by detection of the 14-3-3 protein
858 and, more recently, t-tau in the CSF [66, 183, 184]. Also, CSF
859 NFL recently demonstrated to be a reliable biomarker in the
860 CJD diagnostic workup. Although few studies explored its role
861 as a biomarker in CJD patients so far, CSF NFL levels are
862 significantly increased in CJD (including those with more slow-
863 ly progressive and atypical disease course) compared with AD,
864 FTD, other NDDs (dementia), and controls, indicating a massive
865 synaptic degeneration and neuroaxonal damage in CJD [22, 23,
866 185, 186]. Additionally, it is noteworthy that NFL concentra-
867 tions in CSF appear highly variable among different sCJD sub-
868 types, with higher NFL levels in those with more rapidly
869 progressing disease [187]. Importantly, plasma NFL correlates
870 with CSF NFL concentration and recent studies suggest that
871 blood NFL can accurately reflect the massive neurodegeneration
872 in CJD patients.

NFL as Diagnostic Biomarker

Diagnostic accuracy of serum NFL for discrimination be- 874
875 tween CJD and controls was excellent (Table 2) [185].
876 These findings have been independently replicated in other
877 two studies. Serum NFL distinguished patients from controls
878 with 100% sensitivity and 100% specificity in 45 sCJD pa-
879 tients enrolled in the National Prion Monitoring Cohort [188].
880 Noteworthy, Kovacs and colleagues [189] reported high sen-
881 sitivity and specificity of plasma NFL concentration in dis-
882 criminating CJD subjects from non-CJD controls in a cohort
883 of 132 pathologically classified patients (sCJD, gCJD, and
884 AD cases) showing a rapidly progressive neurological picture.
885 However, in this study, the diagnostic value in the differentiat-
886 ion between prion and other disease cases resulted lower
887 than previously reported investigations (Table 2) [189].
888 Moreover, serum NFL values have been elevated since the
889 early phases of the disease, suggesting a possible role as a
890 screening biomarker [188]. Conversely, serum NFL concen-
891 tration overlapped between ALS and CJD patients in a recent
892 prospective study, even though the size of CJD group was
893 very small [139].

NFL as Staging and Prognostic Biomarker

Longitudinal changes in serum tau and NFL levels were in- 895
896 vestigated in the aforementioned study of Thompson and

colleagues [188]. However, despite a trend toward increasing concentrations of both tau and NFL over the last 12 months before death, at variance with tau, no association was found between serum NFL concentration and speed of decline on the Medical Research Council (MRC) Prion Disease Rating Scale [188]. Also, a recent study strengthens the tight association of plasma tau levels with the rate of disease progression and survival time in sCJD [190].

NFL as Risk/Screening Biomarker

gCJD forms are linked to mutations in the prion protein gene (PRNP) inherited with an autosomal dominant pattern and variable penetrance [191]. The relationship between genotype and phenotype remains a matter of debate, and index cases do not always have a family history [192]. Under this scenario, the discovery of biomarkers serving as surrogates of outcome in clinical trials may be crucial because *PRNP* mutation carriers might benefit from a presymptomatic intervention. PrP-lowering therapeutics are now in preclinical development, and to this end, CSF total PrP has demonstrated to be a strong candidate fluid biomarker showing stable low levels in an ongoing natural history study including presymptomatic mutation carriers and normal controls [193].

Conclusions

The impact of physiological variables on blood NFL concentration, such as sex and age, has not been systematically investigated across published studies. Other variables possibly affecting its modification in peripheral blood, including systemic comorbidities and concomitant drug therapies, were not taken into account. Liver and renal clearance as well as blood cell counts and plasma protein composition could affect biomarker concentrations [194]; however, these factors were not investigated. Indeed, blood NFL concentration alterations associated with renal and hepatic dysfunctions remain unknown, thus representing a potential relevant methodological bias, especially in subjects with NDDs, being generally old and frequently exhibiting vascular comorbidities. In general, blood NFL concentrations correlate with aging due to a subtle axonal degeneration and vascular changes in elderly. However, such an association was clearly absent in CJD, ALS, and AP. This suggests that the probable contribution of aging on NFL concentrations and neurodegeneration becomes trivial in highly aggressive forms of NDDs [195].

Blood NFL concentrations are reported to be massively elevated in ALS patients, even in early disease stages, indicating its value as an efficacious, yet unspecific, biomarker in the differential diagnosis of ALS from ALS mimics. Moreover, blood NFL concentrations can reflect disease severity and/or progression in ALS, suggesting that peripheral NFL could

contribute to support ALS prognosis. Other confounding variables, such as the discordant disease progression in the different clinical subtypes of ALS, should be elucidated in further studies. Actually, blood NFL could help better stratify the multifaceted clinical presentation of ALS phenotypes. However, further studies are needed to confirm its prognostic value. In contrast with genetic forms of AD, blood NFL concentrations are not increased in presymptomatic ALS mutation carriers appearing to tightly link to the symptomatic phase of the disease.

Another NDD where blood NFL increases result impressively is CJD. Because of early diagnosis remains challenging, NFL might be a reliable screening blood-based biomarker with a potentially high negative predictive value for CJD subjects, ruling out more common and less aggressive neurodegenerative dementia, such as AD. Definitely, blood NFL could be of usefulness as a first-step examination to promptly detect CJD during its prodromal phase and to start future disease-modifying treatments. On the other hand, preliminary findings do not support a potential use of NFL as a predictor of longitudinal disease progression in CJD, and its specificity should be further substantiated in comparison with other highly aggressive forms of NDD.

All reported studies showed a good or even excellent diagnostic performance of blood NFL in distinguishing patients with neurodegenerative disorders from HC. The potential contribution of this biomarker candidate to discriminate between different dementia disorders remains ambiguous given the lack of pathognomonic specificity. However, mounting data suggest that blood NFL could be a useful diagnostic tool in the diagnostic workup of FTD, to distinguish FTD (especially FTD with a TDP-43 pathology) from AD patients and to identify PPA with a likely underlying AD pathology, including lvPPA. Moreover, it can represent a biomarker tracking the disease progression and potentially identifying the transition phase from the presymptomatic to the symptomatic stage of the genetic forms of the disease. Most importantly, serum NFL is assumed to be a promising screening tool to rule out an underlying neurodegenerative disease in individuals with psychiatric disorders.

In AD, blood NFL may predict progression to dementia in individuals with MCI at high risk and identify preclinical AD before the conversion phase. Moreover, NFL captures early neurodegenerative changes in presymptomatic familiar AD mutation carriers in which blood NFL concentrations correlate with the predicted time to symptom onset. Further studies are crucial to calculate the negative predictive value of blood NFL as a screening tool in large and selected cohorts of individuals at risk of neurodegeneration and AD, such as individuals with subjective memory complaints and/or decline, late-onset psychiatric disorders, cerebrovascular disease, and diabetes, as well as in aging and elderly individuals in general.

Because of the high negative predictive value of elevated blood NFL concentrations in excluding PD, this candidate biomarker can represent a valid screening tool for clinicians in the early differential diagnosis between PD and AP in cases with confounding clinical presentations. In contrast, blood NFL measurements do not suffice to differentiate PD patients from controls and cannot be used to separate PSP, MSA, and CBD from each other. Nevertheless, blood NFL may be a prognostic tool in clinical practice in both PD and AP patients. Currently, to the best of our knowledge, there are no studies investigating blood NFL in patients with DLB, and few studies are available for PDD patients.

Regarding other relevant clinical neurological presentations, blood NFL may support the classification of sporadic late-onset ataxias, notably helping in differentiating c-MSA-C from SAOA. In choreic patients, blood NFL appears to be a robust prognostic biomarker of HD disease onset and progression and holds potential as a predictive biomarker of response to disease-modifying agents in clinical trials.

Finally, blood NFL seems to be a promising candidate predictor of the timing of clinical phenoconversion in pre-symptomatic mutation carriers with AD, HD, and SCA-3. Conversely, blood NFL concentrations are mostly normal in premanifest ALS and FTD mutation carriers but promptly increase with the onset of clinical symptoms.

In general, given the rapid advances in elucidating the pathophysiological mechanisms of diseases, at the molecular diagnostic level, biomarkers are excellent flexible tools to improve and inform all phases of drug discovery and development by enabling validation of mechanisms of actions [196, 197]. For this reason, NFL is assumed to act as an innovative molecular mechanistic biomarker supporting in vivo detection and the measurement of definite pathophysiological mechanisms across the spectrum of different NDDs. Together with other innovative molecular indicators, NFL will help establish panels of biomarkers—i.e., molecular signatures—encompassing the entire spectrum of molecular events of the NDD spectrum disorders. Applying these molecular signatures in longitudinal investigations will be critical to provide information to depict the pathophysiological processes characterizing different NDDs [198]. These innovative biomarkers will enable the selection of the most appropriate therapies for individual patients by defining which molecular pathophysiological events account for the patient’s clinical symptoms at different stages of the disease [199, 200]. This will establish the grounds to develop effective targeted treatment strategies—i.e., “molecularly” targeted therapies—for the accurate treatment of specific molecular pathophysiological pathways. Future developments in investigating NDD heterogeneity will allow clinicians to deliver targeted interventions that are “customized,” i.e., tailored, to the definite profiles of the individual NDD patient, according to the precision medicine paradigm. Such a precision medicine-based strategy is now increasingly

facing the clinical and biological/genetic complexity and heterogeneity of the various forms of NDD [198]. Precision medicine emphasizes the need of clinical medicine to focus on the pathophysiology of the individual patient, with his/her own distinctive, diverse, and complex matrix of multisystem features [200]. Concerted global efforts will pave the way for a future of neurology, in which drugs will timely and effectively support the prevention and treatment of diseases with very precise biomarker-guided targeted approaches for the right patient at the right time [201].

Acknowledgments H.H. is an employee of Eisai Inc. This work has been performed during his previous position at Sorbonne University, Paris, France. At Sorbonne University, he was supported by the AXA Research Fund, the “Fondation partenariale Sorbonne Université,” and the “Fondation pour la Recherche sur Alzheimer,” Paris, France.

Compliance with Ethical Standards

Competing Interests S.L. received lecture honoraria from Roche and Servier.

H.H. is an employee of Eisai Inc. and serves as Senior Associate Editor for the Journal Alzheimer’s & Dementia and does not receive any fees or honoraria since May 2019; before May 2019, he had received lecture fees from Servier, Biogen, and Roche; research grants from Pfizer, Avid, and MSD Avenir (paid to the institution); travel funding from Functional Neuromodulation, Axovant, Eli Lilly and company, Takeda and Zinfandel, GE Healthcare and Oryzon Genomics; and consultancy fees from Qynapse, Jung Diagnostics, Cytox Ltd., Axovant, Anavex, Takeda and Zinfandel, GE Healthcare, Oryzon Genomics, and Functional Neuromodulation, and he also participated in scientific advisory boards of Functional Neuromodulation, Axovant, Eisai, Eli Lilly and company, Cytox Ltd., GE Healthcare, Takeda and Zinfandel, Oryzon Genomics, and Roche Diagnostics.

He is co-inventor in the following patents as a scientific expert and has received no royalties:

- In Vitro Multiparameter Determination Method for the Diagnosis and Early Diagnosis of Neurodegenerative Disorders Patent Number: 8916388
- In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases Patent Number: 8298784
- Neurodegenerative Markers for Psychiatric Conditions Publication Number: 20120196300
- In Vitro Multiparameter Determination Method for the Diagnosis and Early Diagnosis of Neurodegenerative Disorders Publication Number: 20100062463
- In Vitro Method for the Diagnosis and Early Diagnosis of Neurodegenerative Disorders Publication Number: 20100035286
- In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases Publication Number: 20090263822
- In Vitro Method for the Diagnosis of Neurodegenerative Diseases Patent Number: 7547553
- CSF Diagnostic in Vitro Method for Diagnosis of Dementias and Neuroinflammatory Diseases Publication Number: 20080206797
- In Vitro Method for the Diagnosis of Neurodegenerative Diseases Publication Number: 20080199966
- Neurodegenerative Markers for Psychiatric Conditions Publication Number: 20080131921

1107 G.P., S.M., A.D.V., G.S., U.B., C.A., R.C., and F.B. declare that they
 1108 have no conflicts of interest relevant to this work.

Q5 1109 References

- 1110 1. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010)
 1111 Mechanisms underlying inflammation in neurodegeneration. *Cell*
 1112 140(6):918–934
- 1113 2. Heemels MT (2016) Neurodegenerative diseases. *Nature*
 1114 539(7628):179
- 1115 3. Chi H, Chang HY, Sang TK (2018) Neuronal cell death mecha-
 1116 nisms in major neurodegenerative diseases. *Int J Mol Sci* 19(10):
 1117 3082
- 1118 4. Hampel H, Toschi N, Baldacci F et al (2018) Alzheimer's disease
 1119 biomarker-guided diagnostic workflow using the added value of
 1120 six combined cerebrospinal fluid candidates: A β ₁₋₄₂, total-tau,
 1121 phosphorylated-tau, NFL, neurogranin, and YKL-40. *Alzheimers Dement* 14(4):492–501
- 1122 5. Khalil M, Teunissen CE, Otto M et al (2018) Neurofilaments as
 1123 biomarkers in neurological disorders. *Nat Rev Neurol* 14(10):
 1124 577–589
- 1125 6. Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L,
 1126 Zetterberg H (2019) Neurofilament light chain as a biomarker in
 1127 neurological disorders. *J Neurol Neurosurg Psychiatry* 90(8):870–
 1128 881
- 1129 7. Zhao Y, Xin Y, Meng S, He Z, Hu W (2019) Neurofilament light
 1130 chain protein in neurodegenerative dementia: a systematic review
 1131 and network meta-analysis. *Neurosci Biobehav Rev* 102:123–138
- 1132 8. Kanaan NM, Pigino GF, Brady ST, Lazarov O, Binder LI, Morfini
 1133 GA (2013) Axonal degeneration in Alzheimer's disease: when
 1134 signaling abnormalities meet the axonal transport system. *Exp*
 1135 *Neurol* 246:44–53
- 1136 9. Yuan A, Rao MV, Veeranna NRA (2012) Neurofilaments at a
 1137 glance. *J Cell Sci* 125:3257–3263
- 1138 10. Zetterberg H (2016) Neurofilament light: a dynamic cross-disease
 1139 fluid biomarker for neurodegeneration. *Neuron* 91(1):1–3
- 1140 11. Liu Q, Xie F, Siedlak SL et al (2004) Neurofilament proteins in
 1141 neurodegenerative diseases. *Cell Mol Life Sci* 61(24):3057–3075
- 1142 12. Yuan A, Rao MV, Veeranna NRA (2017) Neurofilaments and
 1143 neurofilament proteins in health and disease. *Cold Spring Harb*
 1144 *Perspect Biol* 9(4):a018309
- 1145 13. Petzold A, Keir G, Warren J, Fox N, Rossor MN (2007) A sys-
 1146 tematic review and meta-analysis of CSF neurofilament protein
 1147 levels as biomarkers in dementia. *Neurodegener Dis* 4(2–3):
 1148 185–194
- 1149 14. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C
 1150 (1996) Patients with amyotrophic lateral sclerosis and other neu-
 1151 rodegenerative diseases have increased levels of neurofilament
 1152 protein in CSF. *J Neurochem* 67(5):2013–2018
- 1153 15. Landqvist Waldo M, Frizell Santillo A et al (2013) Cerebrospinal
 1154 fluid neurofilament light chain protein levels in subtypes of
 1155 frontotemporal dementia. *BMC Neurol* 13:54
- 1156 16. Meeter LH, Dopper EG, Jiskoot LC et al (2016) Neurofilament
 1157 light chain: a biomarker for genetic frontotemporal dementia. *Ann*
 1158 *Clin Transl Neurol* 3(8):623–636
- 1159 17. Hall S, Öhrfelt A, Constantinescu R et al (2012) Accuracy of a
 1160 panel of 5 cerebrospinal fluid biomarkers in the differential diag-
 1161 nosis of patients with dementia and/or parkinsonian disorders.
 1162 *Arch Neurol* 69(11):1445–1452
- 1163 18. Magdalinou NK, Paterson RW, Schott JM et al (2015) A panel of
 1164 nine cerebrospinal fluid biomarkers may identify patients with
 1165 atypical parkinsonian syndromes. *J Neurol Neurosurg Psychiatry*
 1166 86(11):1240–1247
- 1167 19. Vinther-Jensen T, Börnsen L, Budtz-Jørgensen E et al (2016)
 1168 Selected CSF biomarkers indicate no evidence of early neuroin-
 1169 flammation in Huntington disease. *Neurol Neuroimmunol*
 1170 *Neuroinflamm* 3(6):e287
- 1171 20. Lista S, Toschi N, Baldacci F et al (2017) Diagnostic accuracy of
 1172 CSF neurofilament light chain protein in the biomarker-guided
 1173 classification system for Alzheimer's disease. *Neurochem Int*
 1174 108:355–360
- 1175 21. Zetterberg H, Skillbäck T, Mattsson N et al (2016) Association of
 1176 cerebrospinal fluid neurofilament light concentration with
 1177 Alzheimer disease progression. *Jama Neurol* 73(1):60–67
- 1178 22. van Eijk JJ, van Everbroeck B, Abdo WF, Kremer BP, Verbeek
 1179 MM (2010) CSF neurofilament proteins levels are elevated in
 1180 sporadic Creutzfeldt-Jakob disease. *J Alzheimers Dis* 21(2):569–
 1181 576
- 1182 23. Kanata E, Golanska E, Villar-Piqué A et al (2019) Cerebrospinal
 1183 fluid neurofilament light in suspected sporadic Creutzfeldt-Jakob
 1184 disease. *J Clin Neurosci* 60:124–127
- 1185 24. Lycke JN, Karlsson JE, Andersen O, Rosengren LE (1998)
 1186 Neurofilament protein in cerebrospinal fluid: a potential marker
 1187 of activity in multiple sclerosis. *J Neurol Neurosurg Psychiatry*
 1188 64:402–404
- 1189 25. Yilmaz A, Blennow K, Hagberg L et al (2017) Neurofilament
 1190 light chain protein as a marker of neuronal injury: review of its
 1191 use in HIV-1 infection and reference values for HIV-negative
 1192 controls. *Expert Rev Mol Diagn* 17(8):761–770
- 1193 26. Shahim P, Tegner Y, Gustafsson B et al (2016) Neurochemical
 1194 aftermath of repetitive mild traumatic brain injury. *JAMA Neurol*
 1195 73(11):1308–1315
- 1196 27. Pujol-Calderón F, Portelius E, Zetterberg H, Blennow K,
 1197 Rosengren LE, Höglund K (2019) Neurofilament changes in se-
 1198 rum and cerebrospinal fluid after acute ischemic stroke. *Neurosci*
 1199 *Lett* 698:58–63
- 1200 28. Pawlitzki M, Butryn M, Kirchner F et al (2019) CSF
 1201 Neurofilament light chain level predicts axonal damage in cere-
 1202 bral vasculitis. *Ann Clin Transl Neurol* 6(6):1134–1137
- 1203 29. Skillbäck T, Farahmand B, Bartlett JW et al (2014) CSF neurofil-
 1204 ament light differs in neurodegenerative diseases and predicts se-
 1205 verity and survival. *Neurology* 83(21):1945–1953
- 1206 30. Bacioglu M, Maia LF, Preische O et al (2016) Neurofilament light
 1207 chain in blood and CSF as marker of disease progression in mouse
 1208 models and in neurodegenerative diseases. *Neuron* 91:56–66
- 1209 31. Bridel C, van Wieringen WN, Zetterberg H et al (2019)
 1210 Diagnostic value of cerebrospinal fluid neurofilament light pro-
 1211 tein in neurology: a systematic review and meta-analysis. *Jama*
 1212 *Neurol* 76(9):1035–1048
- 1213 32. Mielke MM, Syrjanen JA, Blennow K et al (2019) Plasma and
 1214 CSF neurofilament light: relation to longitudinal neuroimaging
 1215 and cognitive measures. *Neurology* 93(3):e252–e260
- 1216 33. Molinuevo JL, Ayton S, Batrla R et al (2018) Current state of
 1217 Alzheimer's fluid biomarkers. *Acta Neuropathol* 136(6):821–853
- 1218 34. Hampel H, Lista S, Khachaturian ZS (2012) Development of bio-
 1219 markers to chart all Alzheimer's disease stages: the royal road to
 1220 cutting the therapeutic Gordian Knot. *Alzheimers Dement* 8(4):
 1221 312–336
- 1222 35. Baldacci F, Lista S, Garaci F, Bonuccelli U, Toschi N, Hampel H
 1223 (2016) Biomarker-guided classification scheme of neurodegener-
 1224 ative diseases. *J Sport Health Sci* 5(4):383–387
- 1225 36. Hampel H, Frank R, Broich K et al (2010) Biomarkers for
 1226 Alzheimer's disease: academic, industry and regulatory perspec-
 1227 tives. *Nat Rev Drug Discov* 9(7):560–574
- 1228 37. Blennow K, Hampel H, Weiner M, Zetterberg H (2010)
 1229 Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.
 1230 *Nat Rev Neurol* 6(3):131–144
- 1231

38. Zetterberg H, Blennow K (2018) From cerebrospinal fluid to blood: the third wave of fluid biomarkers for Alzheimer's disease. *J Alzheimers Dis* 64(s1):S271–S279
39. Kuhle J, Barro C, Andreasson U et al (2016) Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. *Clin Chem Lab Med* 54(10):1655–1661
40. Gaiottino J, Norgren N, Dobson R et al (2013) Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. *PLoS One* 8(9):e75091
41. Baldacci F, Mazzucchi S, Della Vecchia A et al (2020) The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. *Expert Rev Mol Diagn* 20(4):421–441
42. Califf RM (2018) Biomarker definitions and their applications. *Exp Biol Med (Maywood)* 243(3):213–221
43. Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. *Clin Pharmacol Ther* 69(3):89–95
44. Chen XH, Huang S, Kerr D (2011) Biomarkers in clinical medicine. *IARC Sci Publ* 163:303–322
45. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology* 34:939–944
46. McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 7:263–269
47. Sperling RA, Aisen PS, Beckett LA et al (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 7:280–292
48. Albert MS, DeKosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 7:270–279
49. Dubois B, Feldman HH, Jacova C et al (2014) Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. *Lancet Neurol* 13:614–629
50. Brooks BR (1994) El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. *J Neurol Sci* 124(Suppl):96–107
51. Costa J, Swash M, de Carvalho M (2012) Awaji criteria for the diagnosis of amyotrophic lateral sclerosis: a systematic review. *Arch Neurol* 69:1410–1416
52. Al-Chalabi A, Hardiman O, Kiernan MC, Chiò A, Rix-Brooks B, van den Berg LH (2016) Amyotrophic lateral sclerosis: moving towards a new classification system. *Lancet Neurol* 15(11):1182–1194
53. McKeith IG, Galasko D, Kosaka K et al (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. *Neurology* 47(5):1113–1124
54. McKeith IG, Dickson DW, Lowe J et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. *Neurology* 65(12):1863–1872
55. McKeith IG, Boeve BF, Dickson DW et al (2017) Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. *Neurology* 89(1):88–100
56. Neary D, Snowden JS, Gustafson L et al (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. *Neurology* 51:1546–1554
57. Piguet O, Hornberger M, Mioshi E, Hodges JR (2011) Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. *Lancet Neurol* 10:162–172
58. Gorno-Tempini ML, Hillis AE, Weintraub S et al (2011) Classification of primary progressive aphasia and its variants. *Neurology* 76:1006–1014
59. Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. *J Neurol Neurosurg Psychiatry* 51:745–752
60. Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. *Arch Neurol* 56(1):33–39
61. Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnostic criteria for Parkinson's disease: MDS-PD clinical diagnostic criteria. *Mov Disord* 30(12):1591–1601
62. Litvan I, Agid Y, Calne D et al (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. *Neurology* 47:1–9
63. Gilman S, Wenning GK, Low PA et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. *Neurology* 71(9):670–676
64. Armstrong MJ, Litvan I, Lang AE et al (2013) Criteria for the diagnosis of corticobasal degeneration. *Neurology* 80(5):496–503
65. Hoglinger GU, Respondek G, Stamelou M et al (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. *Mov Disord* 32:853–864
66. World Health Organization (2003) WHO manual for surveillance of human transmissible spongiform encephalopathies, including variant Creutzfeldt-Jakob disease <https://apps.who.int/iris/handle/10665/42656> [Accessed 30 Jan 2003]
67. Manix M, Kalakoti P, Henry M et al (2015) Creutzfeldt-Jakob disease: updated diagnostic criteria, treatment algorithm, and the utility of brain biopsy. *Neurosurg Focus* 39:E2
68. Xia J, Broadhurst DI, Wilson M, Wishart DS (2013) Translational biomarker discovery in clinical metabolomics: an introductory tutorial. *Metabolomics* 9(2):280–299
69. Winblad B, Amouyel P, Andrieu S et al (2016) Defeating Alzheimer's disease and other dementias: a priority for European science and society. *Lancet Neurol* 15(5):455–532
70. Fogel DB (2018) Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. *Contemp Clin Trials Commun* 11:156–164
71. Dubois B (2018) The emergence of a new conceptual framework for Alzheimer's disease. *J Alzheimers Dis* 62(3):1059–1066
72. Beach TG, Monsell SE, Phillips LE, Kukull W (2012) Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. *J Neuropathol Exp Neurol* 71(4):266–273
73. Jack CR Jr, Bennett DA, Blennow K et al (2016) A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. *Neurology* 87(5):539–547
74. Jack CR Jr, Bennett DA, Blennow K et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer's disease. *Alzheimers Dement* 14(4):535–562
75. Hampel H, O'Bryant SE, Molinuevo JL et al (2018) Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. *Nat Rev Neurol* 14(11):639–652
76. Ashton NJ, Leuzy A, Lim YM et al (2019) Increased plasma neurofilament light chain concentration correlates with severity

- of post-mortem neurofibrillary tangle pathology and neurodegeneration. *Acta Neuropathol Commun* 7(1):5
77. Mattsson N, Andreasson U, Zetterberg H, Blennow K, Alzheimer's Disease Neuroimaging Initiative (2017) Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. *Jama Neurol* 74(5):557–566
78. Vågberg M, Norgren N, Dring A et al (2015) Levels and age dependency of neurofilament light and glial fibrillary acidic protein in healthy individuals and their relation to the brain parenchymal fraction. *PLoS One* 10(8):e0135886
79. Khalil M, Pirpamer L, Hofer E et al (2020) Serum neurofilament light levels in normal aging and their association with morphologic brain changes. *Nat Commun* 11(1):812
80. Forgrave LM, Ma M, Best JR, DeMarco ML (2019) The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis: a systematic review and meta-analysis. *Alzheimers Dement (Amst)* 11:730–743
81. Lewczuk P, Ermann N, Andreasson U et al (2018) Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease. *Alzheimers Res Ther* 10(1):71
82. Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K (2019) Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. *JAMA Neurol* 76(7):791–799
83. Pereira JB, Westman E, Hansson O, Alzheimer's Disease Neuroimaging Initiative (2017) Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease. *Neurobiol Aging* 58:14–29
84. Lin YS, Lee WJ, Wang SJ, Fuh JL (2018) Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. *Sci Rep* 8(1):17368
85. Wang SY, Chen W, Xu W et al (2019) Neurofilament light chain in cerebrospinal fluid and blood as a biomarker for neurodegenerative diseases: a systematic review and meta-analysis. *J Alzheimers Dis* 72(4):1353–1361
86. Zhou W, Zhang J, Ye F et al (2017) Plasma neurofilament light chain levels in Alzheimer's disease. *Neurosci Lett* 650:60–64
87. Benedet AL, Ashton NJ, Pascoal TA et al (2019) Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals. *Alzheimers Dement (Amst)* 11:679–689
88. Timmers M, Tesseur I, Bogert J et al (2019) Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease. *Neurobiol Aging* 79:131–141
89. Preische O, Schultz SA, Apel A et al (2019) Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. *Nat Med* 25(2):277–283
90. Hu H, Chen KL, Ou YN et al (2019) Neurofilament light chain plasma concentration predicts neurodegeneration and clinical progression in nondemented elderly adults. *Aging (Albany NY)* 11(17):6904–6914
91. Chatterjee P, Goozee K, Sohrabi HR et al (2018) Association of plasma neurofilament light chain with neocortical amyloid- β load and cognitive performance in cognitively normal elderly participants. *J Alzheimers Dis* 63(2):479–487
92. Mayeli M, Mirshahvalad SM, Aghamollai V, Tafakhori A, Abdolalizadeh A, Rahmani F (2019) Plasma neurofilament light chain levels are associated with cortical hypometabolism in Alzheimer disease signature regions. *J Neuropathol Exp Neurol* nlz054
93. Weston PSJ, Poole T, Ryan NS et al (2017) Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration. *Neurology* 89(21):2167–2175
94. Rascovsky K, Hodges JR, Knopman D et al (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain* 134:2456–2477
95. Erkinen MG, Kim MO, Geschwind MD (2018) Clinical neurology and epidemiology of the major neurodegenerative diseases. *Cold Spring Harb Perspect Biol* 10(4):a033118
96. Bang J, Spina S, Miller BL (2015) Frontotemporal dementia. *Lancet* 386:1672–1682
97. Spinelli EG, Mandelli ML, Miller ZA et al (2017) Typical and atypical pathology in primary progressive aphasia variants. *Ann Neurol* 81:430–443
98. Strong MJ, Abrahams S, Goldstein LH et al (2017) Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. *Amyotroph Lateral Scler Frontotemporal Degener* 18:153–174
99. Rademakers R, Neumann M, Mackenzie IR (2012) Advances in understanding the molecular basis of frontotemporal dementia. *Nat Rev Neurol* 8(8):423–434
100. Ducharme S, Dols A, Laforce R et al (2020) Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. *Brain* 143(6):1632–1650
101. Meeter LH, Kaat LD, Rohrer JD, van Swieten JC (2017) Imaging and fluid biomarkers in frontotemporal dementia. *Nat Rev Neurol* 13(7):406–419
102. Zetterberg H, van Swieten JC, Boxer AL, Rohrer JD (2019) Review: Fluid biomarkers for frontotemporal dementias. *Neuropathol Appl Neurobiol* 45(1):81–87
103. Pijnenburg YA, Verwey NA, van der Flier WM, Scheltens P, Teunissen CE (2015) Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. *Alzheimers Dement (Amst)* 1(4):505–512
104. Ende E, Meeter L, Poos J et al (2019) Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. *Lancet Neurol* 18:1103–1111
105. Steinacker P, Semler E, Anderl-Straub S et al (2017) Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasia. *Neurology* 88:961–969
106. Al Shweiki MR, Steinacker P, Oeckl P et al (2019) Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. *J Psychiatr Res* 113:137–140
107. Katisko K, Cajanus A, Jääskeläinen O et al (2020) Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders. *J Neurol* 267(1):162–167
108. Wilke C, Preische O, Deuschle C et al (2016) Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. *J Neurol Neurosurg Psychiatry* 87:1270–1272
109. Steinacker P, Anderl-Straub S, Diehl-Schmid J et al (2018) Serum neurofilament light chain in behavioral variant frontotemporal dementia. *Neurology* 91(15):e1390–e1401
110. Matias-Guiú JA, Gomez-Pinedo U, Forero L et al (2019) Plasma neurofilament light chain in primary progressive aphasia and related disorders: clinical significance and metabolic correlates. *J Alzheimers Dis* 72:1–10
111. Cellura E, Spataro R, Taiello AC, La Bella V (2012) Factors affecting the diagnostic delay in amyotrophic lateral sclerosis. *Clin Neurol Neurosurg* 114(6):550–554
112. Turner MR, Kiernan MC, Leigh PN, Talbot K (2009) Biomarkers in amyotrophic lateral sclerosis. *Lancet Neurol* 8(1):94–109
113. Lehnert S, Costa J, de Carvalho M et al (2014) Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Frontotemporal Degener* 15(5–6):344–350

- 1491 114. Turner MR, Benatar M (2015) Ensuring continued progress in
1492 biomarkers for amyotrophic lateral sclerosis. *Muscle Nerve*
1493 51(1):14–18
- 1494 115. Xu Z, Henderson RD, David M, McCombe PA (2016)
1495 Neurofilaments as biomarkers for amyotrophic lateral sclerosis:
1496 a systematic review and meta-analysis. *PLoS One* 11(10):
1497 e0164625
- 1498 116. Turner MR, Gray E (2016) Are neurofilaments heading for the
1499 ALS clinic? *J Neurol Neurosurg Psychiatry* 87(1):3–4
- 1500 117. Brettschneider J, Petzold A, Süßmuth SD, Ludolph AC, Tumani
1501 H (2006) Axonal damage markers in cerebrospinal fluid are in-
1502 creased in ALS. *Neurology* 66(6):852–856
- 1503 118. Lin H, Schlaepfer WW (2006) Role of neurofilament aggregation
1504 in motor neuron disease. *Ann Neurol* 60(4):399–406
- 1505 119. Munoz DG, Greene C, Perl DP, Selkoe DJ (1988) Accumulation
1506 of phosphorylated neurofilaments in anterior horn motoneurons of
1507 amyotrophic lateral sclerosis patients. *J Neuropathol Exp Neurol*
1508 47(1):9–18
- 1509 120. Collard JF, Côté F, Julien JP (1995) Defective axonal transport in
1510 a transgenic mouse model of amyotrophic lateral sclerosis. *Nature*
1511 375(6526):61–64
- 1512 121. Lee MK, Marszalek JR, Cleveland DW (1994) A mutant neuro-
1513 filament subunit causes massive, selective motor neuron death:
1514 implications for the pathogenesis of human motor neuron disease.
1515 *Neuron* 13(4):975–988
- 1516 122. Cañete-Soler R, Silberg DG, Gershon MD, Schlaepfer WW
1517 (1999) Mutation in neurofilament transgene implicates RNA pro-
1518 cessing in the pathogenesis of neurodegenerative disease. *J*
1519 *Neurosci* 19(4):1273–1283
- 1520 123. Nie Z, Wu J, Zhai J et al (2002) Untranslated element in neurofil-
1521 ament mRNA has neuropathic effect on motor neurons of trans-
1522 genic mice. *J Neurosci* 22(17):7662–7670
- 1523 124. Zhai J, Lin H, Julien JP, Schlaepfer WW (2007) Disruption of
1524 neurofilament network with aggregation of light neurofilament
1525 protein: a common pathway leading to motor neuron degeneration
1526 due to Charcot-Marie-Tooth disease-linked mutations in NFL and
1527 HSPB1. *Hum Mol Genet* 16(24):3103–3116
- 1528 125. Lin H, Zhai J, Schlaepfer WW (2005) RNA-binding protein is
1529 involved in aggregation of light neurofilament protein and is im-
1530 plicated in the pathogenesis of motor neuron degeneration. *Hum*
1531 *Mol Genet* 14(23):3643–3659
- 1532 126. Watson D (1991) Regional variation in the abundance of axonal
1533 cytoskeletal proteins. *J Neurosci Res* 30(1):226–231
- 1534 127. Reijn TS, Abdo WF, Schelhaas HJ, Verbeek MM (2009) CSF
1535 neurofilament protein analysis in the differential diagnosis of
1536 ALS. *J Neurol* 256(4):615–619
- 1537 128. Steinacker P, Feneberg E, Weishaupt J et al (2016) Neurofilaments
1538 in the diagnosis of motoneuron diseases: a prospective study on 455
1539 patients. *J Neurol Neurosurg Psychiatry* 87(1):12–20
- 1540 129. Tortelli R, Ruggieri M, Cortese R et al (2012) Elevated cerebro-
1541 spinal fluid neurofilament light levels in patients with amyotrophic
1542 lateral sclerosis: a possible marker of disease severity and progres-
1543 sion. *Eur J Neurol* 19(12):1561–1567
- 1544 130. Zetterberg H, Jacobsson J, Rosengren L, Blennow K, Andersen
1545 PM (2007) Cerebrospinal fluid neurofilament light levels in amy-
1546 otrophic lateral sclerosis: impact of SOD1 genotype. *Eur J Neurol*
1547 14(12):1329–1333
- 1548 131. Tortelli R, Copetti M, Ruggieri M et al (2015) Cerebrospinal fluid
1549 neurofilament light chain levels: marker of progression to gener-
1550 alized amyotrophic lateral sclerosis. *Eur J Neurol* 22(1):215–218
- 1551 132. Poesen K, Van Damme P (2019) Diagnostic and prognostic per-
1552 formance of neurofilaments in ALS. *Front Neurol* 9:1167
- 1553 133. Menke RA, Gray E, Lu CH et al (2015) CSF neurofilament light
1554 chain reflects corticospinal tract degeneration in ALS. *Ann Clin*
1555 *Transl Neurol* 2(7):748–755
- 1556 134. Feneberg E, Oeckl P, Steinacker P et al (2018) Multicenter eval-
1557 uation of neurofilaments in early symptom onset amyotrophic lat-
1558 eral sclerosis. *Neurology* 90(1):e22–e30
- 1559 135. Gille B, De Schaepdryver M, Goossens J et al (2019) Serum
1560 neurofilament light chain levels as a marker of upper motor neuron
1561 degeneration in patients with amyotrophic lateral sclerosis.
1562 *Neuropathol Appl Neurobiol* 45(3):291–304
- 1563 136. Lu CH, Macdonald-Wallis C, Gray E et al (2015) Neurofilament
1564 light chain: a prognostic biomarker in amyotrophic lateral sclero-
1565 sis. *Neurology* 84(22):2247–2257
- 1566 137. Gaiani A, Martinelli I, Bello L et al (2017) Diagnostic and prog-
1567 nostic biomarkers in amyotrophic lateral sclerosis: neurofilament
1568 light chain levels in definite subtypes of disease. *Jama Neurol*
1569 74(5):525–532
- 1570 138. Steinacker P, Huss A, Mayer B et al (2017) Diagnostic and prog-
1571 nostic significance of neurofilament light chain NF-L, but not
1572 progranulin and S100B, in the course of amyotrophic lateral scler-
1573 osis: data from the German MND-net. *Amyotroph Lateral Scler*
1574 *Frontotemporal Degener* 18(1–2):112–119
- 1575 139. Verde F, Steinacker P, Weishaupt JH et al (2019) Neurofilament
1576 light chain in serum for the diagnosis of amyotrophic lateral scler-
1577 osis. *J Neurol Neurosurg Psychiatry* 90(2):157–164
- 1578 140. Thouvenot E, Demattei C, Lehmann S et al (2020) Serum neuro-
1579 filament light chain at time of diagnosis is an independent prog-
1580 nostic factor of survival in amyotrophic lateral sclerosis. *Eur J*
1581 *Neurol* 27(2):251–257
- 1582 141. Poesen K, De Schaepdryver M, Stubendorff B et al (2017)
1583 Neurofilament markers for ALS correlate with extent of upper
1584 and lower motor neuron disease. *Neurology* 88(24):2302–2309
- 1585 142. De Schaepdryver M, Lunetta C, Tarlarini C et al (2020)
1586 Neurofilament light chain and C reactive protein explored as pre-
1587 dictors of survival in amyotrophic lateral sclerosis. *J Neurol*
1588 *Neurosurg Psychiatry* 91(4):436–437
- 1589 143. Weydt P, Oeckl P, Huss A et al (2016) Neurofilament levels as
1590 biomarkers in asymptomatic and symptomatic familial amyotro-
1591 phic lateral sclerosis. *Ann Neurol* 79(1):152–158
- 1592 144. Benatar M, Wu J, Andersen PM, Lombardi V, Malaspina A
1593 (2018) Neurofilament light: a candidate biomarker of presymp-
1594 tomatic amyotrophic lateral sclerosis and phenoconversion. *Ann*
1595 *Neurol* 84(1):130–139
- 1596 145. Olsson B, Alberg L, Cullen NC et al (2019) NFL is a marker of
1597 treatment response in children with SMA treated with nusinersen.
1598 *J Neurol* 266(9):2129–2136
- 1599 146. Corey DR (2017) Nusinersen, an antisense oligonucleotide drug
1600 for spinal muscular atrophy. *Nat Neurosci* 20(4):497–499
- 1601 147. Wurster CD, Günther R, Steinacker P et al (2019) Neurochemical
1602 markers in CSF of adolescent and adult SMA patients undergoing
1603 nusinersen treatment. *Ther Adv Neurol Disord* 12:
1604 1756286419846058
- 1605 148. Fratta P, Nirmalanathan N, Masset L et al (2014) Correlation of
1606 clinical and molecular features in spinal bulbar muscular atrophy.
1607 *Neurology* 82(23):2077–2084
- 1608 149. Respondek G, Roeber S, Kretzschmar H et al (2013) Accuracy of
1609 the National Institute for Neurological Disorders and Stroke/Society
1610 for Progressive Supranuclear Palsy and neuroprotection and natural
1611 history in Parkinson plus syndromes criteria for the diagnosis of
1612 progressive supranuclear palsy. *Mov Disord* 28:504–509
- 1613 150. Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino
1614 G (2016) Accuracy of clinical diagnosis of Parkinson disease: a
1615 systematic review and meta-analysis. *Neurology* 86(6):566–576
- 1616 151. Rizzo G, Arcuti S, Copetti M et al (2018) Accuracy of clinical
1617 diagnosis of dementia with Lewy bodies: a systematic review and
1618 meta-analysis. *J Neurol Neurosurg Psychiatry* 89(4):358–366
- 1619 152. Miki Y, Foti SC, Asi YT et al (2019) Improving diagnostic accu-
1620 racy of multiple system atrophy: a clinicopathological study. *Brain*
1621 142(9):2813–2827

153. Abdo WF, Bloem BR, Van Geel WJ, Esselink RA, Verbeek MM (2007) CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. *Neurobiol Aging* 28(5):742–747
154. Herbert MK, Aerts MB, Beenes M et al (2015) CSF neurofilament light chain but not FLT3 ligand discriminates parkinsonian disorders. *Front Neurol* 6:91
155. Tsukamoto K, Matsue E, Kanasaki Y et al (2012) Significance of apparent diffusion coefficient measurement for the differential diagnosis of multiple system atrophy, progressive supranuclear palsy, and Parkinson's disease: evaluation by 3.0-T MR imaging. *Neuroradiology* 54:947–955
156. Hansson O, Janelidze S, Hall S et al (2017) Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. *Neurology* 88:930–937
157. Parnetti L, Gaetani L, Eusebi P et al (2019) CSF and blood biomarkers for Parkinson's disease. *Lancet Neurol* 18(6):573–586
158. Marques TM, van Rumund A, Oeckl P et al (2019) Serum NFL discriminates Parkinson disease from atypical parkinsonisms. *Neurology* 92(13):e1479–e1486
159. Oosterveld LP, Verberk IMW, Majbour NK et al (2020) CSF or serum neurofilament light added to α -synuclein panel discriminates Parkinson's from controls. *Mov Disord* 35(2):288–295
160. Ng ASL, Tan YJ, Yong ACW et al (2020) Utility of plasma neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease. *Mol Neurodegener* 15(1):33
161. Mollenhauer B, Dakna M, Liu T-Y et al (2019) Validation of serum neurofilament light chain as a biomarker of Parkinson's disease progression. *bioRxiv*. Cold Spring Harbor Laboratory; Epub:762237. <https://doi.org/10.1101/762237>
162. Lin CH, Li CH, Yang KC et al (2019) Blood NfL: a biomarker for disease severity and progression in Parkinson disease. *Neurology* 93(11):e1104–e1111
163. Rojas JC, Karydas A, Bang J et al (2016) Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. *Ann Clin Transl Neurol* 3:216–225
164. Donker Kaat L, Meeter LH, Chiu WZ et al (2018) Serum neurofilament light chain in progressive supranuclear palsy. *Parkinsonism Relat Disord* 56:98–101
165. Wilke C, Bender F, Hayer SN et al (2018) Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study. *J Neurol* 265(7):1618–1624
166. Abdo WF, van de Warrenburg BP, Munneke M et al (2006) CSF analysis differentiates multiple-system atrophy from idiopathic late-onset cerebellar ataxia. *Neurology* 67:474–479
167. Li QF, Dong Y, Yang L et al (2019) Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3. *Mol Neurodegener* 14(1):39
168. Zeitberger AM, Thomas-Black G, Garcia-Moreno H et al (2018) Plasma markers of neurodegeneration are raised in Friedreich's ataxia. *Front Cell Neurosci* 12:366
169. Hayer SN, Liepelt I, Barro C et al (2020) NfL and pNfH are increased in Friedreich's ataxia. *J Neurol* 267(5):1420–1430
170. Johnson CD, Davidson BL (2010) Huntington's disease: progress toward effective disease-modifying treatments and a cure. *Hum Mol Genet* 19(R1):R98–R102
171. Bates GP, Dorsey R, Gusella JF et al (2015) Huntington disease. *Nat Rev Dis Primers* 1:15005
172. Craufurd D, MacLeod R, Frontali M et al (2015) Diagnostic genetic testing for Huntington's disease. *Pract Neurol* 15(1):80–84
173. Constantinescu R, Romer M, Oakes D, Rosengren L, Kiebert K (2009) Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington's disease. *Parkinsonism Relat Disord* 15(3):245–248
174. Niemelä V, Landtblom AM, Blennow K, Sundblom J (2017) Tau or neurofilament light-which is the more suitable biomarker for Huntington's disease? *PLoS One* 12(2):e0172762
175. Ross CA, Aylward EH, Wild EJ et al (2014) Huntington disease: natural history, biomarkers and prospects for therapeutics. *Nat Rev Neurol* 10(4):204–216
176. Wild EJ, Boggio R, Langbehn D et al (2015) Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. *J Clin Invest* 125(5):1979–1986
177. Byrne LM, Rodrigues FB, Blennow K et al (2017) Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. *Lancet Neurol* 16(8):601–609
178. Rodrigues FB, Byrne LM, Wild EJ (2018) Biofluid biomarkers in Huntington's disease. *Methods Mol Biol* 1780:329–396
179. Johnson EB, Byrne LM, Gregory S et al (2018) Neurofilament light protein in blood predicts regional atrophy in Huntington disease. *Neurology* 90(8):e717–e723
180. Byrne LM, Rodrigues FB, Johnson EB et al (2018) Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease. *Sci Transl Med* 10(458):eaat7108
181. Uttley L, Carroll C, Wong R, Hilton DA, Stevenson M (2020) Creutzfeldt-Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation. *Lancet Infect Dis* 20(1):e2–e10
182. Parchi P, Giese A, Capellari S et al (1999) Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. *Ann Neurol* 46(2):224–233
183. Zerr I, Kallenberg K, Summers DM et al (2009) Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. *Brain* 132:2659–2668
184. Zanusso G, Fiorini M, Ferrari S et al (2011) Cerebrospinal fluid markers in sporadic Creutzfeldt-Jakob disease. *Int J Mol Sci* 12: 6281–6292
185. Steinacker P, Blennow K, Halbgebauer S et al (2016) Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. *Sci Rep* 6:38737
186. Zerr I, Schmitz M, Karch A et al (2018) Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. *Alzheimers Dement* 14(6):751–763
187. Abu-Rumeileh S, Capellari S, Stanzani-Maserati M et al (2018) The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. *Alzheimers Res Ther* 10(1):3
188. Thompson AGB, Luk C, Heslegrave AJ et al (2018) Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression. *J Neurol Neurosurg Psychiatry* 89(9):955–961
189. Kovacs GG, Andreasson U, Liman V et al (2017) Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort. *Eur J Neurol* 24(11):1326–1e77
190. Staffaroni AM, Kramer AO, Casey M et al (2019) Association of blood and cerebrospinal fluid tau level and other biomarkers with survival time in sporadic Creutzfeldt-Jakob disease. *JAMA Neurol* 76(8):969–977
191. Ladogana A, Kovacs GG (2018) Genetic Creutzfeldt-Jakob disease. *Handb Clin Neurol* 153:219–242
192. Kim MO, Takada LT, Wong K, Forner SA, Geschwind MD (2018) Genetic PrP prion diseases. *Cold Spring Harb Perspect Biol* 10(5):a033134
193. Vallabh SM, Minikel EV, Schreiber SL, Lander ES (2020) Towards a treatment for genetic prion disease: trials and biomarkers. *Lancet Neurol* 19(4):361–368

1753 194. Baldacci F, Lista S, Vergallo A, Palermo G, Giorgi FS, Hampel H 1769
1754 (2019) A frontline defense against neurodegenerative diseases: the 1770
1755 development of early disease detection methods. *Expert Rev Mol* 1771
1756 *Diagn* 19(7):559–563 1772
1757 195. Ashton NJ, Hye A, Rajkumar AP et al (2020) An update on blood- 1773
1758 based biomarkers for non-Alzheimer neurodegenerative disorders. 1774
1759 *Nat Rev Neurol* 16(5):265–284 1775
1760 196. Hampel H, Lista S (2013) Use of biomarkers and imaging to 1776
1761 assess pathophysiology, mechanisms of action and target engage- 1777
1762 ment. *J Nutr Health Aging* 17(1):54–63
1763 197. Hampel H, O’Bryant SE, Castrillo JI et al (2016) Precision med-
1764 icine - the golden gate for detection, treatment and prevention of
1765 Alzheimer’s disease. *J Prev Alzheimers Dis* 3(4):243–259
1766 198. Hampel H, Toschi N, Babiloni C et al (2018) Revolution of
1767 Alzheimer precision neurology. *Passageway of systems biology*
1768 and neurophysiology. *J Alzheimers Dis* 64(s1):S47–S105
1780

199. Hampel H, O’Bryant SE, Durrleman S et al (2017) A precision 1769
medicine initiative for Alzheimer’s disease: the road ahead to 1770
biomarker-guided integrative disease modeling. *Climacteric* 1771
20(2):107–118 1772
200. Hampel H, Vergallo A, Aguilar LF et al (2018) Precision pharma- 1773
cology for Alzheimer’s disease. *Pharmacol Res* 130:331–365 1774
201. Hampel H, Vergallo A, Perry G, Lista S, Alzheimer Precision 1775
Medicine Initiative (APMI) (2019) The Alzheimer Precision 1776
Medicine Initiative. *J Alzheimers Dis* 68(1):1–24 1777

Publisher’s Note Springer Nature remains neutral with regard to jurisdic- 1778
tional claims in published maps and institutional affiliations. 1779

AUTHOR QUERIES

AUTHOR PLEASE ANSWER ALL QUERIES.

- Q1. Please check if the affiliations are captured and presented correctly.
- Q2. Please check if the section headings are assigned to appropriate levels.
- Q3. Please check the provided expanded form for the abbreviation “MMSE” if correct.
- Q4. Please check the word “diseases” inserted after the word “neurodegenerative,” which can be found in the sentence starting “Finally, serum NFL levels were reported relatively lower,” for completeness if correct.
- Q5. References [19, 174], [22, 186], [200, 203] based on original manuscript we received were identical. Hence, the latter was deleted and reference list and citations were adjusted. Please check if appropriate.
- Q6. Please provide complete bibliographic details of this reference.